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ABSTRACT
The p53 tumor suppressor gene product is a key regulator of cell cycle arrest
and apoptosis in vertebrate organisms. Mutations in the p53 gene are commonly
found in human cancers, which may contribute to chemotherapeutic resistance.
These experiments have addressed two distinct aspects of p53 function relating to its
effect on chemotherapeutic resistance and its role as a cell cycle checkpoint.
The effect of p53 genotype of tumor cells on their response to treatment with
the chemotherapeutic agent paclitaxel (trade name Taxol), which stabilizes cellular
microtubules, was tested. Although paclitaxel is broadly effective against human
tumor xenografts in mice, including some known to carry p53 mutations, it was
observed that p53-containing mouse tumor cells were significantly more sensitive
to direct treatment with paclitaxel. In order to reconcile these data, it was tested
whether there was a requirement for p53 in the cytotoxic effects of tumor necrosis
factor-a (TNF-a), a cytokine released from murine macrophages upon paclitaxel
treatment. TNF-a was seen to induce apoptosis in tumor cells independently of p53
genotype. These data suggest that the efficacy of paclitaxel against p53-deficient
tumors could be due in part to its ability to induce local release of TNF-a.
In a separate project, a proposed role for p53 as a checkpoint at mitosis was
investigated. Wild-type and p53 -/- murine fibroblasts were treated with the spindle
inhibitor nocodazole and observed using time-lapse videomicroscopy. Cells of both
genotypes were seen to undergo transient mitotic arrest, indicating that p53 does not
have a checkpoint function at mitosis. However, p53 was found to prevent
nocodazole-treated cells which had adapted out of mitotic arrest from reentering the
cell cycle and initiating another round of DNA synthesis. Despite having a 4N DNA
content, adapted cells are similar to G1 cells in that they have upregulated cyclin E
expression and hypophosphorylated Rb protein. Also, the mechanism of the p53-
dependent arrest in adapted cells requires the cyclin-dependent kinase inhibitor p21.
Taken as a whole, these data suggest that the p53-dependent checkpoint following
spindle disruption functionally overlaps with the p53-dependent checkpoint
following DNA damage.
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Chapter 1
Overview of p53 and microtubule-acting drugs
The p53 tumor suppressor gene is a key regulator of cell cycle arrest and apoptosis in
vertebrate organisms. In order to divide successfully and maintain the fidelity of
their DNA, cells must be able to arrest their progression through the cell cycle to
wait for more favorable growth conditions or to carry out necessary repairs.
Furthermore, when cells have sustained extensive genetic or structural damage,
they must be able to activate the cell's intrinsic suicide program, known as
apoptosis. Such cells may have gained oncogenic mutations, so that failure to
eliminate them could lead to the onset of tumors in the organism. The p53 tumor
suppressor gene product is a component of cellular signalling pathways resulting in
cell cycle arrest and apoptosis, and therefore plays an important role in governing
cell behavior in response to many different environmental stimuli.
In this chapter, I intend to review current understanding of the role of p53 in
human cancer, the known regulatory functions of p53, and the mechanism of action
of the p53 protein. I will then provide background information for the two distinct
research projects described in Chapters 2 and 3 of this document. As background for
Chapter 2, I will discuss relevant literature on the chemotherapeutic agent
paclitaxel, and how p53 may affect the response of cells to treatment with this drug.
Furthermore, in preparation for Chapter 3, I will discuss mitotic checkpoints, and
review literature regarding p53's recently proposed role as a cell cycle checkpoint at
mitosis.
I. The tumor suppressor gene p53
The p53 gene has been extensively studied because of its role in tumor
development. Much is known about p53 mutations and the tumor types in which
they are likely to occur. Below, I have summarized the effect of germline and
somatic p53 mutations in human cancer. Additionally, I briefly review information
gained from mouse models of p53 inactivation.
p53 mutations in human cancer
The p53 gene has been identified as the most frequently mutated gene in human
cancer, with mutations detected in over 50% of all tumors analyzed (Hollstein et al.,
1994). Absence of functional p53 protein through either inherited or spontaneous
somatic mutation is associated with increased tumor predisposition in humans. In
a rare heritable condition known as Li-Fraumeni syndrome, a p53 allele containing
a point mutation is passed through the germline of affected individuals (Malkin et
al., 1990). Families in these pedigrees exhibit very high incidences of tumors of
several different tissue types, including breast carcinomas, soft tissue sarcomas, brain
tumors, and osteosarcomas. Analysis of tumor DNAs from Li-Fraumeni patients
reveals retention of the point-mutated p53 allele accompanied by loss of the
remaining wild-type p53 allele (Malkin et al., 1990). Thus, p53 acts as a tumor
suppressor gene, because inactivation of both copies of the gene is necessary in order
to promote tumorigenesis.
A far more common means by which p53 inactivation promotes tumorigenesis is
via spontaneous mutation in somatic tissues. Consecutive sporadic mutations of
both p53 alleles in the same somatic cell effectively eliminate p53's tumor
suppressor function, in accordance with the two-hit model originally described by
Knudson (Knudson 1971). This mechanism appears to be a common occurrence in
tumor development, given the high percentage of sporadic tumors which contain
p53 mutations. Interestingly, p53 mutations have been detected in tumors of many
different tissue types, including lung, breast, colon, bladder, brain, and
hematopoietic tissue (Hollstein et al., 1991). Thus, the specific mechanism of the p53
protein allows it to act as a global suppressor of tumorigenesis.
Mouse knockout model
A variety of vertebrate organisms contain homologues of the p53 gene, including
Mus musculus (Lane and Crawford 1979; Linzer and Levine 1979), chicken (Soussi et
al., 1988), and Xenopus laevis (Soussi et al., 1987). The tumor suppression function
of p53 appears to be conserved in at least one of these species, the mouse. Knockout
mouse models of p53 have been constructed in which p53 has been inactivated in
the germline using gene replacement techniques. Mice which are homozygous for
the disrupted p53 allele all show greatly increased tumor frequency, rapidly
developing thymic lymphomas and dying by age six months, one quarter of their
normal lifespan (Donehower et al., 1992; Jacks et al., 1994). Heterozygous animals
are also predisposed to tumor development, and develop thymic lymphomas and a
variety of different sarcomas by nine months of age. In addition to the information
gained from the knockout animals themselves, fibroblasts generated from knockout
animals have been an extremely useful reagent for dissecting p53 function at the
cellular level. These cells, which are devoid of functional p53, can be analyzed for
their growth characteristics in different environments to identify circumstances in
which p53 function is required for normal growth regulation. These cells and
clones derived from them have been the primary reagent used in this work, as
described in chapters 2 and 3.
p53 and cell cycle checkpoints
p53 inhibits cellular proliferation by two general pathways, cell cycle arrest and
apoptosis. In its arrest function, p53 acts to induce cell cycle arrest in G1 in cells
which have experienced DNA damage. The role of p53 in the cellular response to
DNA damage was initially suggested by the observation that levels of p53 protein
increased in myeloid cells following ionizing radiation (Kastan et al., 1991). The p53
protein was subsequently demonstrated to be a necessary component of the G1
checkpoint activated after DNA damage in normal fibroblasts, in experiments
utilizing p53-deficient fibroblasts generated from knockout mice. After treatment
with ionizing radiation, the percentage of wild-type fibroblasts still in S phase was
found to drop nearly to zero, while the fraction of p53 -/- fibroblasts in S phase
remained virtually unchanged (Kastan et al., 1992). These data indicate that p53 is a
primary upstream component of the G1 arrest pathway. Such a checkpoint is
believed to provide cells which have sustained DNA damage with an opportunity
to repair their DNA before initiating DNA synthesis (Donehower and Bradley 1993).
Cells which lack p53 would not pause for repairs and could fix radiation-induced
alterations in their genome by progressing into S phase with damaged DNA. For
this reason, the ability of the p53 protein to help implement G1 arrest has been
described as a means of ensuring genomic stability (Lane 1992). In support of this
view, cells lacking p53 have been shown to undergo gene amplification when placed
under selective pressure (Livingstone et al., 1992). The p53 protein has also been
found to induce arrest in GO when levels of ribonucleoside triphosphate pools fall
below a critical threshold (Linke et al., 1996). In this pathway, p53 again appears to
maintain genomic stability by regulating S phase entry, as cells which began DNA
replication without adequate supplies of nucleotides could suffer catastrophic DNA
damage.
In addition to its regulatory role in G1, the p53 protein has been proposed to regulate
checkpoints at other phases of the cell cycle, including G2 and M. Several groups
have utilized conditional expression of p53 protein in cells using temperature-
sensitive or tetracycline-inducible constructs to analyze its function during different
phases of the cell cycle (Agarwal et al., 1995; Guillouf et al., 1995; Stewart et al., 1995).
Depending on the timing of p53 induction, such cell lines were observed to arrest in
the G2 phase of the cell cycle, indicating that p53 is capable of inducing arrest in G2.
However, it cannot yet be definitively concluded that p53 is a physiological
component of a G2 checkpoint, because these experiments required the expression of
high levels of p53 protein from nonhomologous promoters. Other data suggestive
of a role for p53 in G2 include the observation that the p53 protein is phosphorylated
in vitro by CDKs specific to the S and G2 phases of the cell cycle, resulting in
stimulation of sequence-specific DNA binding by p53 (Wang and Prives 1995). It has
further been suggested that p53 is a component of a checkpoint at mitosis, based on
the arrest phenotype of p53-deficient fibroblasts following disruption of the mitotic
spindle (Cross et al., 1995). The evidence for a p53-dependent checkpoint at mitosis
is discussed in detail later in this chapter; experimental evidence addressing this
question is presented in Chapter 3.
p53 and apoptosis
p53 also regulates cell proliferation via a second pathway, activation of apoptosis.
The role of p53 in apoptosis was first defined by Yonish-Rouach and colleagues, who
observed that myeloid leukemic cells transfected with wild-type p53 protein rapidly
underwent apoptosis (Yonish-Rouach et al., 1991). Subsequently, it was
demonstrated that the p53 protein was required for induction of cell death in a
physiological setting, in immature thymocytes following DNA damage (Clarke et al.,
1993; Lowe et al., 1993b). Later research suggests that this may reflect a role for p53 in
eliminating thymocytes with faulty or incomplete antigen receptor gene
rearrangements, which could produce oncogenic mutations (Guidos et al., 1996;
Nacht et al., 1996). Subsequently, p53 has also been found to be necessary for
induction of apoptosis in abnormally proliferating fibroblasts. Normal fibroblasts
which have been transformed by the addition of oncogenes such as c-myc,
adenovirus ElA, and activated H-ras undergo apoptosis when grown in medium
depleted of growth factors. However, similarly transformed p53-deficient fibroblasts
do not undergo apoptosis in identical conditions (Hermeking and Eick 1994; Lowe et
al., 1994b). Thus, one aspect of p53's function as a tumor suppressor may be to
suppress tumorigenesis by inducing apoptosis in transformed cells which fail to
arrest under growth-limiting conditions. Interestingly, oncogenically transformed
cells growing in a solid tumor, where they are in conditions of limiting oxygen, also
undergo p53-dependent apoptosis (Graeber et al., 1996). These observations suggest
that a physiological selective pressure exists for p53 mutations during tumor
development. Cells which have gained oncogenic mutations and are proliferating
inappropriately are eliminated by apoptosis, unless they have also inactivated the
apoptotic pathway.
p53-dependent apoptosis has also been observed to occur in abnormally proliferating
fibroblasts following treatment with certain chemotherapeutic agents or ionizing
radiation (Lowe et al., 1993a). This result is noteworthy, because it implies that p53
status may affect the response of tumors to therapy (discussed at greater length in
p53 and cancer treatment, below). However, it is important to note that not all
forms of apoptosis require p53. For instance, apoptosis in immature thymocytes
following treatment with glucocorticoids does not require p53 (Clarke et al., 1993;
Lowe et al., 1993b), nor does interdigital apoptosis during embryonic development,
nor apoptosis during mammary involution, as these processes occur normally in
the p53 -/- mouse (Donehower et al., 1992; Jacks et al., 1994). Thus, while p53 is an
upstream molecule in several pathways leading to cell death, it is not a required
component of the apoptotic machinery.
Mechanism of the p53 protein
The biochemical function of the p53 protein is a transcription factor. The protein
was shown to bind DNA in a sequence-specific manner, and the p53 binding site has
been mapped to two copies of the 10 base pair motif 5'-
PuPuPuC(A/T)(A/T)GPyPyPy-3' (Kern et al., 1991; Vogelstein and Kinzler 1992).
Wild-type p53 protein is able to activate transcription in vitro from reporter
constructs which contain the p53 consensus sequence, while mutant p53 protein
fails to do so (Farmer et al., 1992; Kern et al., 1992; Zambetti et al., 1992). In vivo, p53
activates transcription from a number of different target genes, which are described
in detail below.
Structure of the p53 protein
The p53 protein itself consists of three domains: an N-terminal transactivation
domain, a central DNA-binding domain, and a C-terminal oligomerization domain.
The N-terminal domain of the protein has been demonstrated to bind several
general transcription factors, including TATA-box binding protein (TBP) (Horikoshi
et al., 1995), the p62 subunit of TFIIH (Xiao et al., 1994), and several TBP-associated
factors (TAFs) (Lu and Levine 1995; Thut et al., 1995). p53 increases transcription of
its target genes by localization of these molecules to the promoter region, as
mutations which disrupt the interactions between p53 and its TAFs render the
protein incapable of activating transcription (Lin et al., 1994). The central portion of
the p53 protein contains the sequence-specific DNA binding domain. This domain
is the most frequent site of point mutations in the gene, indicating that sequence-
specific binding is crucial to its activity (Hollstein et al., 1994). Crystal structure
analysis of the p53 protein-DNA complex has revealed that the point mutations
disrupt DNA binding interactions (Cho et al., 1994). Thus, the spectrum of p53
mutations in tumors strongly supports the link between its tumor suppression
activity and its function as a transcription factor. It has also been observed that the
p53 protein can act as a repressor of transcription when cotransfected with a number
of different genes (Donehower and Bradley 1993, and references therein). This
repression only occurs with promoters containing a TATA box (Mack et al., 1993);
therefore, it may be due to sequestration of TBP and other transcription factors by
the large quantities of p53 protein expressed in these experiments.
Structurally, the active form of the p53 protein consists of a tetramer. The molecule
is formed of two homodimers, which are linked by the C-terminal oligomerization
domain (Clore et al., 1994). The C-terminal portion of the protein may help regulate
p53 activity, as p53 appears to require a conformational change in order to sequence-
specifically bind DNA. Deletion of the C-terminal domain of p53 results in
activation of DNA binding, as does interaction with short single strands of DNA
(Hupp and Lane 1994; Jayaraman and Prives 1995). The mechanism by which the C-
terminal domain regulates the DNA binding domain of the protein has not yet been
fully elucidated.
The p53 protein contains multiple phosphorylation sites in both the N-terminal
transcriptional activation domain and the C-terminal oligomerization domain (rev.
in Ko and Prives 1996). A number of protein kinases have been shown to
phosphorylate p53 in vitro, including double-stranded DNA-activated protein
kinase (DNA-PK), cyclin-dependent kinases, casein kinases I and II, and protein
kinase C (rev. in Meek 1994). Historically, the importance of these phosphorylation
sites in the p53 protein has been unclear, as mutation of individual or multiple
phosphorylation sites was seen to affect the transcriptional activity of p53 in some
instances but not in others (rev. in Ko and Prives 1996). However, recent reports
demonstrate a direct link between phosphorylation of p53 and activation of the
protein following DNA damage. Shieh et al found that after DNA damage, p53
became phosphorylated by DNA-PK at serine residue 15 in the N-terminus (Shieh et
al., 1997). This phosphorylation decreased the interaction between p53 and its
negative regulator MDM2, resulting in increased transactivation by p53. Siliciano
and colleagues also identified serine 15 as a residue which became phosphorylated
after DNA damage, and reported that this modification was associated with
enhanced transcription of p53 target genes (Siliciano et al., 1997). Thus,
phosphorylation of a residue in the N-terminus of p53 by DNA-PK may regulate its
activity following DNA damage.
p53-responsive genes
p53 activates transcription from a number of different target genes, at least some of
which appear to function in cell cycle arrest and apoptosis. One major
transcriptional target of p53 is the p21 gene, which was identified by at least three
different screening techniques (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al.,
1993). The p21 protein is an inhibitor of cyclin-dependent kinase molecules (CDKs).
Upon induction of expression by p53, p 21 inhibits cell cycle progression by binding to
CDKs which are expressed in GI. The ability of p53 to cause cell cycle arrest in G1 is
dependent in large part on its ability to induce expression of p21 as knockout
fibroblasts lacking p53 or p21 both fail to arrest in G1 following DNA damage
(Brugarolas et al., 1995; Deng et al., 1995). However, at least one additional,
unidentified p53 target gene must contribute to the p53-dependent G1 arrest, as the
arrest phenotype of p21-deficient cells is slightly less pronounced than that of p53
deficient cells.
Another gene whose transcription is upregulated in response to p53 expression is
the bax gene (Miyashita and Reed 1995). Bax has been shown to promote apoptosis
in a number of different cell types. The Bax protein has homology to the survival
factor Bcl-2, which inhibits apoptosis (Oltvai and Korsmeyer 1994). Bax and Bcl-2 are
capable of forming homo- and heterodimers; thus, by increasing Bax levels, p53 can
alter the ratio of the two proteins and effectively shift a cell's fate towards induction
of apoptosis. A mouse knockout model for Bax has been constructed, and the mice
display no increased tumor predisposition, unlike p53-deficient mice (Knudson et
al., 1995). These results could be interpreted to mean that Bax does not significantly
contribute to the ability of p53 to induce apoptosis. However, other research would
seem to indicate that Bax does play an important role in p53-dependent apoptosis.
McCurrach et al found that ElA-expressing fibroblasts, which undergo p53-
dependent apoptosis when subjected to DNA damage, displayed partial resistance to
apoptosis when the Bax protein was not present (McCurrach et al., 1997).
Additionally, Yin and colleagues reported that absence of Bax in a transgenic mouse
tumor model led to accelerated tumor growth and decreased levels of apoptosis (Yin
et al., 1997). Transgenic mice which retained functional Bax displayed p53-
dependent expression of the Bax gene in tumors, suggesting that in this model
system, the p53 protein inhibits tumor progression by inducing apoptosis through
Bax.
Several other genes have been identified as p53-responsive genes, with functions
that may also affect control of proliferation. The cyclin G gene, which is induced in
a p53-dependent manner following DNA damage, encodes a novel cyclin with no
identified CDK partner (Okamoto and Beach 1994). The GADD45 gene is also
induced after DNA damage (Kastan et al., 1992), and appears to play a role in the
DNA repair process (Smith et al., 1994). The death receptor-5 gene (DR5) has
recently been identified as a p53-inducible gene following DNA damage (Wu et al.,
1997). DR5 is one of several receptors for the apoptosis-inducing ligand TRAIL, a
member of the tumor necrosis factor ligand family (Sheridan et al., 1997). Another
p53 response gene is insulin-like growth factor binding protein 3 gene (IGF-BP3),
which is induced after DNA damage (Buckbinder et al., 1995). The IGF-BP3 protein
may inhibit cell proliferation by repressing signalling by insulin-like growth factors.
Finally, Polyak and colleagues have identified a group of transcripts induced in p53-
expressing tumor cells undergoing apoptosis (Polyak et al., 1997). Interestingly,
many of these genes were found to encode proteins involved in oxidative stress.
These results suggested a model in which activation of p53 could lead to apoptosis
by generation of reactive oxygen species, which cause degradation of mitochondrial
components and cell death. A number of other genes have been proposed to be
transcriptional targets of p53, as screens for p53-response genes continue.
Transcriptional activity of p53 and apoptosis
One area in which the mechanism of activity of the p53 protein remains unclear is
induction of apoptosis. Although its transcriptional activity is clearly important to
its function in inducing growth arrest, there have been conflicting reports as to
whether p53-mediated transcription is required for induction of the cell death
pathway. The p53 protein has been shown to induce apoptosis in cells treated with
transcriptional and translational inhibitors, suggesting that no new transcription or
protein synthesis is needed for p53-dependent apoptosis to occur (Caelles et al., 1994;
Wagner et al., 1994). Also, truncated and point-mutated versions of the p53 protein
which lacked transcriptional activity were found to be capable of inducing cell death
when transfected into HeLa cells, although at a slower rate than when
transactivation-competent p53 was added (Haupt et al., 1995). Interestingly, a
mutant p53 sequence derived from a human tumor was found to be competent for
transcriptional activation and induction of G1 arrest, yet unable to induce apoptosis
when transformed into rodent cells, possibly indicating that the point mutation
affected some other aspect of p53 function (Rowan et al., 1996).
In contrast to these data, Sabbatini et al. reported that a double-point mutant version
of p53 which lacked the ability to activate or repress transcription from promoters
containing p53-binding sequences was compromised in its ability to induce
apoptosis (Sabbatini et al., 1995). Attardi et al. also found transcriptional activation
to be essential for p53 to cause apoptosis (Attardi et al., 1996). In their experimental
system, wild-type and mutant p53 constructs were microinjected into p53-deficient
E1A-expressing fibroblasts, which were subsequently assayed for apoptosis. Versions
of the p53 protein which lacked the N-terminal transactivation domain or the C-
terminal oligomerization domain or which contained point mutations commonly
found in human tumors did not induce cell death in this assay. Moreover, the
ability of p53 deletion constructs to induce apoptosis could be reconstituted by
addition of a nonhomologous transcriptional activation domain or oligomerization
domain. Further research will be necessary in order to resolve the question of how
transcriptional activation affects the ability of the p53 protein to induce apoptosis.
p53 and cancer treatment
In addition to providing cells with a selective advantage during tumor formation,
p53 mutations have also been found to affect the response of tumors to therapy. In
general, the frequency of p53 mutations in various tumor types correlates with their
therapeutic responsiveness (Lowe 1995). For example, cancers of the lung, colon,
prostate and bladder all have a high incidence of p53 mutations (Takahashi et al.,
1989; Fearon and Vogelstein 1990; Isaacs et al., 1991; Sidransky et al., 1991). These
tumor types often respond poorly to treatment with chemotherapeutic drugs or
radiation (Lowe et al., 1994c). Other kinds of tumors have been noted to have a very
low frequency of p53 mutations, such as testicular teratocarcinomas and childhood
acute lymphoblastic leukemias (Jonveaux and Berger 1991; Heimdal et al., 1993;
Lutzker and Levine 1996). In contrast to the previous group of tumor types, these
tumors are often extremely responsive to therapy. For instance, every testicular
teratocarcinoma examined appears to have wild-type p53 protein; 90-95% of these
tumors are cured by treatment with the chemotherapeutic cisplatin (Levine 1997).
Furthermore, while lymphoblastic leukemias generally are responsive to treatment,
a certain fraction do undergo relapse. In these cases, failure of therapy can be
correlated with the occurrence of mutations in the p53 gene (Felix et al., 1992;
Yeargin et al., 1993).
The significance of p53 mutations in tumor responsiveness has also been examined
by determining the p53 status of individual tumors and correlating it with their
response to therapy. These studies confirm and extend the more general correlation
between p53 status, tumor type, and therapeutic efficacy described above. In one
clinical study, aberrant expression of p53 protein, an indicator of the presence of
missense mutations in p53, was found to be associated with resistance to cisplatin
therapy in non-small cell lung cancer (Rusch et al., 1995). At least two groups have
addressed the effect of p53 mutations in individual breast cancer patients. Bergh et
al. observed that chemotherapy and local radiotherapy were less effective against
breast cancers which contained p53 mutations (Bergh et al., 1995). Also, Aas et al.
have demonstrated that specific mutations in the p53 gene predict primary
resistance to therapy with doxorubicin and early relapse in breast cancer patients
(Aas et al., 1996). A final tumor type in which p53 status appears to affect therapeutic
response is Wilms' tumor, a childhood cancer of the kidney. Most Wilms' tumors
do not contain p53 mutations and usually are successfully treated. However,
Wilms' tumors which displayed anaplastic morphology were found to have
frequent p53 mutations and a significantly worse prognosis and response to
treatment (Bardeesy et al., 1994).
One potential explanation for the correlation between p53 status and tumor
responsiveness has been provided by experiments using p53 knockout cells in
conjunction with murine tumor models. Wild-type murine fibroblasts transformed
with the oncogenes ElA and Ras undergo apoptosis when treated with anticancer
agents (Lowe et al., 1993a). However, p53-deficient fibroblasts transformed with the
same oncogenes fail to die after treatment. Since p53 is known to regulate initiation
of apoptosis, this raised the possibility that chemotherapeutic agents and radiation
might be acting by inducing apoptosis. This hypothesis was tested in vivo using a
genetically controlled system, in which p53 +/+ and p53 -/- tumors were generated
in nude mice and then treated with radiation or the chemotherapeutic adriamycin
(Lowe et al., 1994a). Upon treatment, p53 +/+ tumors regressed and contained large
numbers of apoptotic cells, while p53 -/- tumors failed to respond and had a low
apoptotic index. Furthermore, when several p53 +/+ tumors which had initially
responded to treatment underwent a relapse, these tumors were found to have
acquired p53 mutations rendering them resistant to apoptosis. Thus, the
effectiveness of chemotherapeutic agents and radiation treatment may depend in
part on the ability of these treatments to activate p53-dependent apoptosis in tumor
cells. In this model, tumors which have acquired p53 mutations are resistant to
undergoing apoptosis and therefore survive such treatments.
The concept of p53-dependent apoptosis as a component of therapeutic effectiveness
reflects a change in understanding of how anticancer treatments work. Many
anticancer therapies, including ionizing radiation and several common
antineoplastic drugs, induce DNA damage or interfere with DNA replication. For
example, the chemotherapeutic cisplatin causes DNA damage by intercalating
between DNA strands, while the drug adriamycin prevents the topoisomerase
enzyme from separating DNA strands during DNA replication. Historically, the
mechanism of these drugs has been assumed to be via genotoxic damage to cancer
cells, which were assumed to be more sensitive to these agents due to their escalated
rate of proliferation. However, emerging data suggests that these drugs may act in
part by induction of apoptosis in tumor cells, which initiate apoptosis more readily
because of their transformed status (Fisher 1994). As the p53 status of a tumor
impacts strongly on its ability to undergo apoptosis, this new model may explain in
part why p53 mutation is so strongly correlated with poor response to treatment
(Lowe 1995). Of course, the p53 status of a tumor is not the sole determinant of
successful treatment. Other genetic factors that could affect tumor responsiveness to
therapy include amplification of the multidrug resistance gene, mdm2, and
mutations in other components of the apoptotic signalling pathway and machinery.
However, because the p53 status of a tumor may be one of the major factors affecting
therapeutic success, one of the high priorities of biomedical research is finding
therapies which are effective against tumors with mutated p53.
p53 and microtubule-acting drugs
As discussed earlier, the p53 protein clearly plays a central role in cellular pathways
which trigger responses to DNA damage. One interesting question is whether p53
can act as a sensor for disruptions in the cell other than DNA damage, such as
microtubule damage. Given that p53 is also a component of signalling pathways
which detect more general environmental stresses, such as hypoxia and inadequate
nutrient supply (Lowe et al., 1994b; Graeber et al., 1996), it is not an unreasonable
hypothesis that the stress of microtubule damage might activate a p53-dependent
signalling pathway.
The microtubule cytoskeleton plays a vital role during cell division and in
interphase functions of the cell, such as intracellular transport, maintenance of
cellular shape, and cell motility. Microtubules are formed of tubulin dimers, each of
which is composed of an a-tubulin and a P-tubulin molecule. Microtubules exist
in a dynamic equilibrium with their tubulin subunits, enabling the microtubule
network to undergo flexible rearrangement by assembling and disassembling
microtubules. This property of dynamic instability is crucial to completing normal
cellular division. During mitosis, the microtubule network is remodelled to form
the mitotic spindle, which serves to align chromosomes at metaphase and separate
sister chromatids during anaphase and telophase. A number of drugs exist which
inhibit mitosis by binding to tubulin subunits or intact microtubules, thus shifting
the equilibrium towards depolymerization or stabilization of microtubules. These
drugs disrupt the microtubules which comprise the mitotic spindle, thereby
inhibiting cell division. Depending on the cell type treated and dosage, such drugs
can induce cell cycle arrest or cell death.
One primary goal of this work was to determine whether microtubule-acting drugs
function via p53-dependent mechanisms. If this were the case, it could indicate a
link between p53 and the microtubule cytoskeleton, which would identify a new
p53-dependent signalling pathway. Because the upstream signals leading to p53
activation have not been elucidated clearly, identification of a novel upstream
stimulus would be a useful tool for further research. Alternatively, if microtubule-
acting drugs were found to be wholly p53-independent in their action, they would
have enormous potential as a novel class of antiproliferative agent. As mentioned
above, many chemotherapeutic drugs act by causing DNA damage or inhibiting
DNA metabolism, which leads to activation of p53-dependent pathways.
Identification of antiproliferative drugs which act by p53-independent mechanisms
would be potentially valuable for biomedical research, as these drugs might prove
effective against tumors containing p53 mutations.
II. The chemotherapeutic agent paclitaxel
Paclitaxel (trade name Taxol) was identified in 1971 following a screen by the
National Cancer Institute for compounds with cytotoxic activity. The original
source of the drug was from the bark of the Pacific yew tree (Taxus brevifolia).
However, scarcity of this natural resource and the difficulty in purification led to the
development of chemical synthesis protocols (Nicolaou et al., 1994). Among
chemotherapeutic agents, paclitaxel has a unique activity in that it binds to and
stabilizes cellular microtubules. Other microtubule-acting drugs have been widely
used as anticancer agents, such as vincristine and vinblastine, members of the Vinca
alkaloid family. However, these drugs all act by binding to free tubulin subunits and
thus promoting disassembly of microtubules. The novel mechanism of paclitaxel
raised hopes that it would prove effective against tumors which were refractory to
other therapies.
Preclinical and clinical testing
In the National Cancer Institute screen, paclitaxel was found to have cytotoxic effects
against a panel of different tumor cell lines, including murine L1210, P388, and
P1534 leukemias, Walker 256 carcinosarcoma, sarcoma 180, and Lewis lung tumor
(National Cancer Institute, 1983). However, the compound was not selected for
clinical development at that time because it did not appear to be significantly more
effective against experimental tumors than other agents under development.
Paclitaxel was later tested against murine B16 melanoma and displayed significant
activity, providing impetus for its further development as a clinical drug (Rowinsky
et al., 1990). As further characterization of its activity, paclitaxel was tested against
several xenografts of human tumors in the DCT screening tumor panel. It was
found to induce regression or significant growth delay in a number of tumors,
including human CX-1 colon tumors, LX-1 lung tumors, MX-1 mammary tumors,
and intraperitoneally implanted murine P388 and L1210 leukemias (National
Cancer Institute, 1983). In addition, paclitaxel was tested against other tumor
xenografts in studies by independent investigators. Riondel et al. found that
paclitaxel demonstrated activity against xenografts of primary tumors of the breast,
ovary, endometrium, lung, tongue, and brain (Riondel et al., 1986). Paclitaxel was
also effective against a different panel of human tumors transplanted into mice,
including A431 vulva, A2780 ovarian, H2981 and L2987 lung, and RCA and HCT-116
colon carcinomas (Rose 1993). The drug was seen to be ineffective in some
instances, such as against xenografts of pancreatic carcinoma and M5076 sarcoma
(Sternberg et al., 1987; Rose 1993).
Early clinical trials of paclitaxel were carried out in the mid-1980s against a number
of different human solid tumors and leukemias. In phase 1 trials, several groups
reported problems with acute hypersensitivity reactions in patients, and
development of the drug was nearly halted. However, paclitaxel did demonstrate
antineoplastic activity against melanomas, ovarian carcinomas, non-small cell lung
carcinomas, and several other tumor types (Rowinsky et al., 1990). Paclitaxel
appeared more promising during phase 2 trials, when it was found to be effective
against ovarian carcinomas and melanomas (Rowinsky and Donehower 1995). In
particular, the efficacy of the drug against refractory ovarian carcinomas caused
excitement. Paclitaxel was observed to have an overall response rate of 37% against
advanced ovarian cancers, many of which were resistant to treatment with the
chemotherapeutic cisplatin (Thigpen et al., 1994). Paclitaxel was also found to
display substantial antitumor activity against metastatic breast cancer, with a
response rate of over 50% in women who had previously received other forms of
chemotherapy (Holmes et al., 1991). Currently, paclitaxel is used effectively against a
number of different tumor types, including cancers of the ovary, breast, head and
neck, and lung (Rowinsky and Donehower 1995).
Cellular effects of paclitaxel
The best known activity of paclitaxel is its ability to bind to and stabilize
microtubules. Schiff et al. first characterized the action of paclitaxel in vitro, and
reported that it was able to promote microtubule assembly (Schiff et al., 1979).
Paclitaxel was observed to decrease the lag time required for microtubule assembly
and shift the equilibrium for assembly in favor of microtubules, effectively
decreasing the concentration of tubulin needed to promote assembly. Also,
microtubules formed in the presence of taxol were more stable, and were resistant to
undergoing depolymerization when placed in the cold (4°C) or in CaC12 (4 mM).
Paclitaxel was shown in photoaffinity studies to have a binding site on the P3-tubulin
subunit of the tubulin dimer in microtubule polymers, although it did not bind free
tubulin (Rao et al., 1992). In a later report, an electron crystallography study of
paclitaxel bound to microtubules showed that one molecule of paclitaxel was bound
per tubulin dimer (Nogales et al., 1995). Furthermore, it was observed that the
binding site of paclitaxel spanned the region where interactions occurred between
protofilaments of the microtubule. This finding was consistent with the
preferential binding of paclitaxel to polymerized tubulin.
Paclitaxel was also characterized by examining its effect on cells in tissue culture.
Schiff and Horwitz treated human and mouse fibroblasts with the drug, and
reported that cells accumulated in the G2 and M portions of the cell cycle when
grown in medium containing 10 jgM paclitaxel (Schiff and Horwitz 1980). The
treated cells were seen to contain bundles of cytoplasmic microtubules which were
unusually stable, and had large increases in their total microtubule mass. It was
concluded that the cells were unable to depolymerize these cytoplasmic
microtubules to form the mitotic spindle, resulting in their arrest just prior to
mitosis. De Brabander et al. also observed that when present at micromolar
concentrations, paclitaxel induced massive assembly of free microtubules in cells
(DeBrabander et al., 1981). Thus, when present at high concentration, paclitaxel
induces polymerization of cytoplasmic tubulin and prevents assembly of the mitotic
spindle. More recent studies have focused on the effects on paclitaxel at low
(nanomolar) concentrations. Jordan et al. found that at a dose of 8 nM, paclitaxel did
not cause any increase in microtubule polymer mass, but was still capable of
inhibiting cell proliferation in HeLa cells (Jordan et al., 1993). Long and Fairchild
made a similar observation, reporting that 4 nM concentrations of paclitaxel were
sufficient to inhibit mitotic progression in human colon carcinoma cells (Long and
Fairchild 1994). These results suggest that at low concentrations, paclitaxel prevents
cell proliferation by stabilizing the microtubules of the mitotic spindle. This
inhibition of dynamic instability has also been observed to occur when cells are
treated with low concentrations of microtubule depolymerizing agents, such as
vincristine, vinblastine, and nocodazole (Jordan et al., 1991; Vasquez et al., 1997).
Thus, paclitaxel may affect cellular microtubules by different mechanisms at
different concentrations.
In addition to its effects on cellular microtubules, paclitaxel has an additional
activity which is potentially relevant to its antineoplastic properties - specifically, the
ability to mimic bacterial lipopolysaccharide (LPS) and trigger an immune response
in macrophages. LPS is a major component of the coat of Gram-negative bacteria.
When macrophages are exposed to LPS, they respond by releasing a number of
different inflammatory mediators, including tumor necrosis factor-a (TNF-a),
interleukin-1, interleukin-6, interferon-a, interferon-0, and reactive oxygen and
nitrogen intermediates (Vogel et al., 1995). Ding et al. discovered that like LPS,
paclitaxel could elicit release of TNF-a from murine macrophages (Ding et al., 1990).
This effect was mediated via the same pathway as LPS signalling, as macrophages
derived from LPS-hyporesponsive mice failed to secrete TNF-a in response to either
paclitaxel or LPS. It was subsequently shown that paclitaxel induced expression of a
group of genes known to be upregulated by LPS (Manthey et al., 1992). Also,
paclitaxel induced tyrosine phosphorylation of the erkl and erk2 proteins, which are
phosphorylated upon LPS stimulation.
The ability of paclitaxel to activate the LPS signalling pathway was shown to be
distinct from its microtubule-stabilizing activity. As part of attempts to increase the
supply of the drug, a number of paclitaxel-related compounds and partial structures
were purified. Burkhart et al. performed experiments using several of these
paclitaxel analogs and demonstrated that the two activities of paclitaxel could be
separated (Burkhart et al., 1994). For instance, the paclitaxel-related compound
taxotere was more effective at stabilizing microtubules than paclitaxel, but did not
induce any expression of TNF-a. Similar analysis of a number of different analogs
supported the conclusion that these effects of paclitaxel occurred via distinct
pathways, as no correlation was found between the ability of a compound to stabilize
microtubules and its ability to induce release of TNF-a. One intriguing possibility
raised by these results was that the activity of paclitaxel as a chemotherapeutic agent
against human cancers might depend in part on its ability to induce TNF-a
secretion. However, it is important to note that the LPS-mimetic effects of paclitaxel
were found to differ between human and murine macrophages. In murine
macrophages, treatment with paclitaxel alone stimulated TNF-a secretion. In
human macrophages, paclitaxel enhanced TNF-ac secretion when given in
conjunction with very low doses of LPS, but when given alone was not capable of
inducing TNF-a secretion (Allen et al., 1993).
Tumor necrosis factor-oa
The release of TNF-a from macrophages upon paclitaxel treatment is particularly
interesting given the historic ability of this molecule to induce cell death and tumor
regression. In the late 1800s, Dr. William Coley utilized the antitumor properties of
TNF-a by administering LPS-containing bacterial extracts to his cancer patients
(Vogel et al., 1995). The resulting TNF-a release caused tumor regression in some
patients, but was accompanied by toxic side effects from severe inflammatory
responses. Because of its ability to induce tumor regression, TNF-a has undergone
considerable testing as an anticancer agent in various animal tumor models and in
patients during the past two decades (Spriggs and Yates 1992). It has shown limited
success in these systems, as systemic administration has caused severe side effects
and relatively poor inhibition of tumor growth. However, some studies utilizing
local administration of TNF-a have had more encouraging results, showing
cytotoxicity against tumors and reduced severity of side effects. For instance, TNF-a
was effective in melanoma patients when administered regionally in combination
with chemotherapy (Lejeune et al., 1994). TNF-a also demonstrated
antiproliferative activity in combination therapies against xenografts of human
renal cell carcinoma, L1210 leukemia, and murine sarcoma (Baisch et al., 1990;
Asher et al., 1991; Lasek et al., 1995).
TNF-a has been shown to be capable of inducing apoptosis in a number of cell types,
which may contribute to its antitumor activity. The molecular signalling pathway
activated by TNF-(a has been rapidly elucidated (rev. in Cleveland and Ihle 1995, and
Baker and Reddy 1996). A member of the Fas ligand family, TNF-a is a trimer, and
binds to a trimeric transmembrane receptor molecule. The TNF-a receptor contains
a 'death domain', a unique cytoplasmic motif found in both the TNF-a receptor and
the Fas receptor that is responsible for generating cytotoxic death signals. This
domain is capable of activating an apoptotic pathway by interacting with a number
of different downstream adaptor molecules, including TRADD, FADD, and RIP.
Modulation of the activity of these signalling molecules by the TNF-a receptor
ultimately leads to activation of cysteine proteases, resulting in apoptosis.
Paclitaxel efficacy and p53 status
When considering the efficacy of paclitaxel as a chemotherapeutic agent, one
important question to resolve is whether it functions via a p53-dependent pathway,
as many tumors contain p53 mutations. A body of data would seem to suggest that
the activity of paclitaxel is independent of p53. First, the antiproliferative
mechanism of paclitaxel appears to be unrelated to the p53 pathway, as paclitaxel
affects cellular microtubules, while p53 is understood primarily for its role in
detecting DNA damage. Additionally, data obtained from preclinical and clinical
testing of paclitaxel would suggest that it does not rely on functional p53 protein to
cause tumor regression. In particular, the efficacy of paclitaxel against cisplatin-
resistant tumors could reflect activity in a clinical setting where cells contained
mutated p53 (Thigpen et al., 1994). Because cisplatin is known to cause DNA
damage, thereby activating a p53-dependent pathway, tumors which proved
resistant to cisplatin therapy are likely to contain p53 mutations. Successful
treatment of these tumors with paclitaxel could potentially be due to p53-
independent effects of the drug. In preclinical testing, paclitaxel was demonstrated
to have widespread activity against a number of different xenografts of human
tumors in mice, few of which have been screened for their p53 status but at least
some of which are likely to contain p53 mutations (National Cancer Institute, 1983;
Riondel et al., 1986; Rose 1993). In several instances, tumor cell lines used in
xenograft experiments were actually demonstrated to contain mutated p53. For
instance, paclitaxel was found to be effective in preclinical testing against the human
tumors CX-1 (colon), A431 (vulva), and FaDu (hypopharynx) (National Cancer
Institute, 1983; Rose 1993; Joschko et al., 1994), all of which are documented to have
p53 mutations (Baker et al., 1989; Reiss et al., 1992). Finally, wild-type and p53-
heterozygous human lymphoblastoid cells were found to have similar sensitivities
to treatment with paclitaxel in vitro (Delia et al., 1996).
Other data indicate that the antiproliferative effects of paclitaxel may be affected by
p53 status, although the correlation between these two factors is unclear. Wahl et al.
observed that human fibroblasts with inactivated p53 were more sensitive to
paclitaxel treatment than wild-type fibroblasts, with an increased proportion of p53-
deficient cells undergoing cell cycle arrest and apoptosis (Wahl et al., 1996). Another
in vitro study has also found a positive correlation between p53 mutation and
increased paclitaxel sensitivity in fibroblasts (Hawkins et al., 1996). Conversely,
inactivation of p53 was found to render ovarian teratocarcinoma cells more
resistant to undergoing apoptosis following paclitaxel treatment, indicating a
correlation between p53 mutation and paclitaxel resistance (Wu and El-Deiry 1996).
Also, in a clinical study, Rosellet al. looked for a link between paclitaxel sensitivity
and p53 status in non-small cell lung cancer, and hypothesized that p53 mutation
possibly could be prognostic of paclitaxel resistance (Rosell et al., 1995). Finally,
although disruption of microtubules has not been directly linked to a p53-dependent
signalling pathway, it is not unreasonable to suppose that p53 could detect this
stimulus, as p53 has been shown to detect other general cellular stresses such as
hypoxia and inadequate nutrient supply (Lowe et al., 1994b; Graeber et al., 1996). In
Chapter 2, I will provide data describing how the p53 status of tumor cells affects
their response to paclitaxel in one specific experimental system.
III. p53 function and mitosis
The p53 protein has been established as an important cell cycle regulator because of
its function as a checkpoint in G1. This aspect of p53 function has been well-
documented and widely studied. However, p53 has also been proposed to act as part
of a cell cycle checkpoint at mitosis after microtubule disruption. Identification of a
novel checkpoint regulated by p53 would be significant, because it could relate to
p53's role as a tumor suppressor gene. The third chapter of this thesis addresses the
role of p53 in a cell cycle checkpoint activated by microtubule-acting drugs, which
induce cell cycle arrest at mitosis.
The spindle assembly checkpoint
Proper assembly of the mitotic spindle is an important event in the cell cycle that is
monitored by a cell cycle checkpoint (rev. in Rudner and Murray 1996). If the
spindle fails to function properly, chromosome loss or gain can result, which is
detrimental to the organism. Loss of chromosomes can cause cell death, while gain
of additional chromosomes can lead to birth defects or increase the tendency of a cell
to become tumorigenic. In order to reduce the occurrence of these errors, cells have
evolved a spindle assembly checkpoint, which monitors spindle structure,
attachment of chromosomes to spindle microtubules, and alignment of
chromosomes on the spindle. Activation of the spindle assembly checkpoint causes
a delay in the onset of chromosome segregation until the problem is corrected.
One convenient way to study the spindle assembly checkpoint is to activate it
artificially by treating cells with microtubule-acting drugs. A number of drugs exist
which are used for this purpose in the laboratory. In particular, drugs which
destabilize microtubules are used commonly in experimental settings, such as
benomyl, nocodazole, colcemid, colchicine, and members of the Vinca alkaloid
family (e.g., vincristine, vinblastine, and vindesine). At high concentrations, these
drugs act by binding to free tubulin, preventing it from polymerizing into
microtubules and in some cases promoting the disassembly of existing cellular
microtubules (Himes et al., 1976; Hoebeke et al., 1976; Owellen et al., 1976). At lower
concentrations, these drugs do not alter the amount of total tubulin polymer, but are
still capable of inhibiting cell proliferation by altering the dynamic instability of
spindle microtubules (Jordan et al., 1991; Vasquez et al., 1997). Specifically, cells
treated with such drugs are unable to add and remove tubulin subunits from the
ends of spindle microtubules, resulting in an inhibition of spindle function. For
example, Jordan et al. found that treatment of HeLa cells with low concentrations of
vincristine or vinblastine inhibited cell proliferation without causing any detectable
microtubule depolymerization or spindle disorganization (Jordan et al., 1991).
Treatment of cells with microtubule-destabilizing drugs results in cell cycle arrest at
mitosis, indicating that the spindle assembly checkpoint can detect inappropriate
depolymerization or stabilization of spindle microtubules. However, this mitotic
arrest state is not maintained indefinitely, as some cell types treated with
microtubule-acting drugs for a prolonged period of time eventually undergo
adaptation (Kung et al., 1990; Rieder and Palazzo 1992). In these instances, cells
return to an interphase state despite the lack of a functional spindle.
A number of genes have been identified which are components of the mitotic
checkpoint mechanism. Hoyt et al. performed a screen for mutant strains of S.
cerevisiae which failed to arrest at mitosis following treatment with the
microtubule-destabilizing drug benomyl (Hoyt et al., 1991). They isolated several
different mutants which continued to progress through the cell cycle, termed bub
mutants (for "budding uninhibited by benzimidazole"). The phenotype of bub
mutant strains in the presence of drug was continued budding and DNA replication
without cytokinesis, leading to benzimidazole-induced lethality. The three B UB
genes were later cloned and were found to encode a protein kinase, its target, and a
third protein of unknown function (Roberts et al., 1994). A murine homolog of
BUB1 has also been identified, and was found to localize to the kinetochore (Taylor
and McKeon 1997). Li and Murray also carried out a screen for checkpoint-defective
mutants, by identifying S. cerevisiae which did not delay completion of mitosis in
the presence of benomyl (Li and Murray 1991). Like the bub mutants, the mad
(mitotic arrest-deficient) mutants isolated in this screen exhibited increased lethality
in the presence of drug due to continued cell cycle progression without a functional
spindle. The MAD gene products are proteins of unknown function which appear
to be involved in a signal transduction cascade in combination with the BUB
proteins, based on genetic and biochemical studies (Rudner and Murray 1996).
Human and Xenopus homologs of the MAD2 gene product have been identified
and were shown to localize to free kinetochores (Chen et al., 1996; Li and Benezra
1996).
Evidence for a p53-dependent checkpoint at mitosis
The concept that the p53 protein could be a component of the mitotic spindle
checkpoint was first suggested by Cross et al. (Cross et al., 1995). They observed that
upon treatment of wild-type fibroblasts with microtubule-acting drugs, the cells
arrested with a 4N DNA content, presumably because of disruption of the mitotic
spindle. However, p53 -/- fibroblasts treated in the same manner failed to arrest,
instead proceeding to enter another round of S phase and become 8N. Because the
phenotype observed in p53 -/- cells was similar to that observed in yeast strains with
mutations in the BUB and MAD genes, which become polyploid upon treatment
with spindle inhibitors, it was proposed that p53 might function at the mitotic
checkpoint. Two other groups have also reported that cells without functional p53
protein undergo inappropriate DNA replication in the presence of mitotic spindle
inhibitors. Minn et al. found that a murine prolymphocytic cell line with inactive
p53 protein became polyploid after treatment with nocodazole, while Di Leonardo et
al. observed that p53-deficient mouse or human fibroblasts underwent continued
DNA replication in the presence of colcemid or nocodazole (Minn et al., 1996; Di
Leonardo et al., 1997). Also, p53 -/- fibroblasts have been noted to become tetraploid
at a high frequency, which could be indicative of a defect in the spindle checkpoint
(Livingstone et al., 1992).
Other groups have provided additional evidence for a role for p53 at mitosis by
examining effects of p53 on the centrosome, the organizing center for the
microtubules of the mitotic spindle. The p53 protein was seen to localize to the
mitotic spindle using indirect immunofluorescence techniques, and a fraction of p53
protein was shown to copurify with the centrosomal protein pericentrin (Brown et
al., 1994). Fukusawa et al. reported that p53 -/- fibroblasts had multiple copies of
functional centrosomes, resulting in unequal segregation of chromosomes at
mitosis (Fukasawa et al., 1996). In this same study, p53 -/- cells appeared to have a
defect in the regulation of centrosome duplication. Biochemical evidence can also
be interpreted as indicative of p53 activity at mitosis. Wang and Prives found that
cyclin-dependent kinases expressed during G2 and M were capable of
phosphorylating p53 protein in vitro and stimulating its sequence-specific DNA
binding activity (Wang and Prives 1995). Furthermore, the levels of
transcriptionally active p53 protein have been shown to increase after treatment of
cells with the microtubule-acting drugs paclitaxel, vinblastine, and nocodazole,
suggesting that the stress of microtubule damage may result in activation of a p53-
dependent response pathway (Tishler et al., 1995).
Evidence against a p53-dependent checkpoint at mitosis
Despite the data discussed above, the function of p53 following microtubule
disruption remains unclear. Minn et al. examined in detail the response of a
prolymphocytic cell line to treatment with nocodazole (Minn et al., 1996). Drug-
treated cells were seen to arrest transiently at mitosis, then adapt into an interphase
state, as is often observed with cells treated for long intervals with microtubule-
acting drugs (Kung et al., 1990; Rieder and Palazzo 1992). Wild-type cells remained
arrested in the interphase state, while cells without functional p53 continued cell
cycle progression in the absence of cytokinesis and became polyploid. As previously
reported, p53 protein was found to be induced in nocodazole-treated cells following
spindle damage (Tishler et al., 1995; Minn et al., 1996). However, levels of p53
protein did not increase immediately upon nocodazole treatment, but after the time
window in which cells adapted. Thus, while p53 protein helped prevent
nocodazole-treated cells from continuing DNA synthesis, it did not appear to be
required until after cells had adapted from mitotic arrest. The data of Minn et al.
would indicate that p53 does not act as a checkpoint at mitosis, but instead functions
after cells have returned to an interphase state. The third chapter of this thesis
characterizes the checkpoint function of p53 after mitosis by examining the response
of wild-type and p53-deficient fibroblasts to treatment with nocodazole.
The work presented in this thesis describes two distinct projects which examine how
the p53 status of cells affects their response to microtubule-acting drugs. Chapter 2
will analyze how the p53 status of transformed fibroblasts determines their response
to the microtubule-polymerizing agent paclitaxel, and will describe effects of
paclitaxel that are independent of p53 status. Chapter 3 will address whether p53 acts
as a component of a checkpoint at mitosis by examining how the p53 status of
normal fibroblasts affects their ability to undergo cell cycle arrest in response to the
microtubule-depolymerizing drug nocodazole.
References
Aas, T., A. L. Borreson, S. Geisler, B. Smith-Sorensen, H. Johnsen, J. E. Varhaug, L.
A. Akslen, and P. E. Lonning (1996). Specific P53 mutations are associated with de
novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2: 811-814.
Agarwal, M. L., A. Agarwal, W. R. Taylor, and G. R. Stark (1995). p53 controls both
the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in
human fibroblasts. Proc. Natl. Acad. Sci. USA 92: 8493-8497.
Allen, J., S. A. Moore, and M. D. Wewers (1993). Taxol enhances but does not induce
interleukin-1B and tumor necrosis factor-alpha production. J. Lab. Clin. Med. 122(4):
374-381.
Asher, A. L., J. J. Mule, A. Kasid, N. P. Restifo, J. C. Salo, C. M. Reichert, G. Jaffe, B.
Fendly, M. Kriegler, and S. A. Roseberg (1991). Murine tumor cells transduced with
the gene for tumor necrosis factor-alpha. J. Immunol. 146(9): 3227-3234.
Attardi, L. D., S. W. Lowe, J. Brugarolas, and T. Jacks (1996). Transcriptional
activation by p53, but not induction of the p21 gene, is essential for oncogene-
mediated apoptosis. EMBO J. 15: 3693-3701.
Baisch, H., U. Otto, and G. Kloppel (1990). Antiproliferative and cytotoxic effects of
single and combined treatment with tumor necrosis factor alpha and or interferon
alpha on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell
kinetic studies. Cancer Res. 50: 6389-6395.
Baker, S. J., E. R. Fearon, J. M. Nigro, S. R. Hamilton, A.C. Preisinger, J. M. Jessup, P.
VanTuinen, D. H. Ledbetter, D. F. Barker, Y. Nakamura, R. White, and B. Vogelstein
(1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
Science 244: 217-221.
Baker, S. J., and E. P. Reddy (1996). Transducers of life and death: TNF receptor
superfamily and associated proteins. Oncogene 12: 1-9.
Bardeesy, N., D. Falkoff, M. J. Petruzzi, N. Nowak, B. Zabel, M. Adam, M. C. Aguiar,
P. Grundy, T. Shows, and J. Pelletier (1994). Anaplastic Wilms' tumour, a subtype
displaying poor prognosis, harbors p53 gene mutations. Nature Genetics 7: 91-97.
Bergh, J., T. Norberg, S. Sjogren, A. Lindgren, and L. Holmberg (1995). Complete
sequencing of the p53 gene provides prognostic information in breast cancer
patients, particularly in relation to adjuvant systemic therapy and radiotherapy.
Nat. Med. 1: 1029-1034.
Brown, C. R., S. J. Doxsey, E. White, and W. J. Welch (1994). Both viral (adenovirus
E1B) and cellular (hsp70, p53) components interact with centrosomes. J. Cell
Physiol. 160 (1): 47-60.
Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon
(1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature
377: 552-557.
Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Selzinger,
and N. Kley (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53.
Nature 377: 646-649.
Burkhart, C. A., J. W. Berman, C. S. Swindell, and S. B. Horwitz (1994). Relationship
between the structure of taxol and other taxanes on induction of tumor necrosis
factor-alpha gene expression and cytotoxicity. Cancer Res. 54: 5779-5782.
Caelles, C., A. Helmberg, and M. Karin (1994). p53-dependent apoptosis in the
absence of transcriptional activation of p53-target genes. Nature 370: 220-223.
Chen, R.-H., J. C. Waters, E. D. Salmon, and A. W. Murray (1996). Association of
spindle assembly checkpoint XMAD2 with unattached kinetochores. Science 274:
242-246.
Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich (1994). Crystal structure of a p53
tumor suppressor-DNA complex: understanding tumorigenic mutations. Science
265: 346-355.
Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and
A. H. Wyllie (1993). Thymocyte apoptosis induced by p53-dependent and
independent pathways. Nature 362: 849-852.
Cleveland, J. L., and J. N. Ihle (1995). Contenders in FasL/TNF death signalling. Cell
81: 479-482.
Clore, G. M., J. G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella,
and A. M. Gronenborn (1994). High-resolution structure of the oligomerization
domain of p53 by multidimensional NMR. Science 265: 386-390.
Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W.
H. Raskind, and B. J. Reid (1995). A p53-dependent mouse spindle checkpoint.
Science 267: 1353-1356.
DeBrabander, M., G. Geuens, R. Nuydens, R. Willebrords, and J. DeMey (1981).
Taxol induces the assembly of free microtubules in living cells and blocks the
organizing capacity of the centrosomes and kinetochores. Proc. Natl. Acad. Sci. USA
78: 5608-5612.
Delia, D., S. Mizutani, G. Lamorte, K. Goi, S. Iwata, and M. A. Pierotti (1996). p53
activity and chemotherapy. Nat. Med. 2(7): 724-725.
Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder (1995). Mice lacking
p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint
control. Cell 82: 675-684.
Di Leonardo, A., S. H. Khan, S. P. Linke, V. Greco, G. Seidita, and G. M. Wahl (1997).
DNA rereplication in the presence of mitotic spindle inhibitors in human and
mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57: 1013-1019.
Ding, A. H., F. Porteau, E. Sanchez, and C. F. Nathan (1990). Shared actions of
endotoxin and taxol on TNF receptors and TNF release. Science 248: 370-372.
Donehower, L. A., and A. Bradley (1993). The tumor suppressor p53. Biochem.
Biophys. Acta 1155: 181-205.
Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, J. S.
Butel, and A. Bradley (1992). Mice deficient for p53 are developmentally normal but
susceptible to spontaneous tumours. Nature 356: 215-221.
El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D.
Lin, W. E. Mercer, K. Kinzler, and B. Vogelstein (1993). WAF1, a potential mediator
of p53 tumor suppression. Cell 75: 817-825.
Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives (1992).
Wild-type p53 activates transcription in vitro. Nature 358: 83-86.
Fearon, E. R., and B. Vogelstein (1990). A genetic model for colorectal
tumorigenesis. Cell 61: 759-767.
Felix, C. A., M. M. Nau, T. Takahashi, T. Mitsudomi, I. Chiba, D. G. Poplack, G. H.
Reaman, D. E. Cole, J. J. Letterio, J. Whang-Peng, T. Knutsen, and J. D. Minna (1992).
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic
leukemia. J. Clin. Invest. 89: 640-647.
Fisher, D. E. (1994). Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-
542.
Fukasawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude (1996).
Abnormal centrosome amplification in the absence of p53. Science 271: 1744-1747.
Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A.
J. Giaccia (1996). Hypoxia-mediated selection of cells with diminished apoptotic
potential in solid tumours. Nature 379: 88-91. 4
Guidos, C. J., C. J. Williams, I. Grandal, G. Knowles, M. T. Huang, and J. S. Danska
(1996). V(D)J recombination activates a p53-dependent DNA damage checkpoint in
scid lymphocyte precursors. Genes Dev. 10: 2038-2054.
Guillouf, C., F. Rossell, K. Krishnaraju, E. Moustacchi, B. Hoffman, and D. A.
Liebermann (1995). p5 3 involvement in control of G2 exit of the cell cycle: role in
DNA damage-induced apoptosis. Oncogene 10: 2263-2270.
Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge (1993). The p21
Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases.
Cell 75: 805-816.
Haupt, Y., S. Rowan, E. Shaulian, K. H. Vousden, and M. Oren (1995). Induction of
apoptosis in HeLa cells by transactivation-deficient p53. Genes Dev. 9: 2170-2183.
Hawkins, D. S., G. W. Demers, and D. A. Galloway (1996). Inactivation of p53
enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56: 892-898.
Heimdal, K., R. A. Lothe, S. Lystad, R. Holm, S. D. Fossa, and A. L. Borreson (1993).
No germline TP53 mutations detected in familial and bilateral testicular cancer.
Genes Chromosom. Cancer 6: 92-97.
Hermeking, H., and D. Eick (1994). Mediation of c-myc-induced apoptosis by p53.
Science 265: 2091-2093.
Himes, R. H., R. N. Kersey, I. Heller-Bettinger, and F. E. Samson (1976). Action of
the Vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on
microtubules in vitro. Cancer Res. 36: 3798-3802.
Hoebeke, J., G. Van Nijen, and M. DeBrabander (1976). Interactions of nocodazole (R
17934), a new antitumoral drug, with rat brain tubulin. Biochem. Biophys. Res.
Commun. 69: 319-324.
Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B.
Smith-Sorenson, R. Montesano, and C. C. Harris (1994). Database of p53 somatic
gene mutations in human tumors and cell lines. Nuc. Acid Res. 22(17): 3551-3555.
Hollstein, M., D. Sidranksy, B. Vogelstein, and C. C. Harris (1991). p53 mutations in
human cancers. Science 253: 49-53.
Holmes, F. A., R. S. Walters, R. L. Theriault, A. D. Forman, L. K. Newton, M. N.
Raber, A. U. Buzdar, D. K. Frye, and G. N. Hortobagyi (1991). Phase II trial of taxol,
an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83:
1797-1805.
Horikoshi, N., A. Usheva, J. Chen, A. J. Levine, R. Weinmann, and T. Shenk (1995).
Two domains of p53 interact with the TATA-binding protein, and the adenovirus
13S ElA protein disrupts the association, relieving p53-mediated transcriptional
repression. Mol. Cell. Biol. 15: 227-234.
Hoyt, M. A., L. Totis, and B. T. Roberts (1991). S. cerevisiae genes required for cell
cycle arrest in response to loss of microtubule function. Cell 66: 507-517.
Hupp, T. R., and D. P. Lane (1994). Allosteric activation of latent p53 tetramers.
Curr. Biol. 4: 865-875.
Isaacs, W. B., B. S. Carter, and C. M. Ewing (1991). Wild-type p53 suppresses growth
of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51: 4716-
4720.
Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson,
and R. A. Weinberg (1994). Tumor spectrum analysis in p53-mutant mice. Curr.
Biol. 4(1): 1-7.
Jayaraman, L., and C. Prives (1995). Activation of p53 sequence-specific DNA
binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-
1029.
Jonveaux, P., and R. Berger (1991). Infrequent mutations in the P53 gene in primary
human T-cell acute lymphoblastic leukemia. Leukemia 5: 839-840.
Jordan, M. A., D. Thrower, and L. Wilson (1991). Mechanism of inhibition of cell
proliferation by Vinca alkaloids. Cancer Res. 51: 2212-2222.
Jordan, M. A., R. J. Toso, D. Thrower, and L. Wilson (1993). Mechanism of mitotic
block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl
Acad Sci USA 90: 9552-9556.
Joschko, M. A., L. K. Weber, J. Groves, D. L. Ball, and J. F. Bishop (1994). Radiation
enhancement by taxol in a squamous carcinoma of the hypopharynx (FaDu) in nude
mice. Proc. Am. Assoc. Cancer Res. 35: 647.
Kastan, M., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett,
B. Vogelstein, and A. J. Fomace Jr. (1992). A mammalian cell cycle checkpoint
pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71(4):
587-597.
Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig (1991).
Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:
6304-6311.
Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B.
Vogelstein (1991). Identification of p53 as a sequence-specific DNA binding protein.
Science 252: 1708-1711.
Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B.
Vogelstein (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression.
Science 256: 827-830.
Knudson, C. M., K. S. Tung, W. G. Tourtellotte, G. A. Brown, and S. J. Korsmeyer
(1995). Bax-deficient mice with lymphoid hyperplasia and male germ cell death.
Science 270: 96-99.
Knudson, A. G. (1971). Mutation and cancer: statistical study of retinoblastoma.
Proc. Natl. Acad. Sci. USA 68: 820-823.
Ko, L. J., and C. Prives (1996). p53: puzzle and paradigm. Genes Dev. 10: 1054-1072.
Kung, A. L., S. W. Sherwood, and R. T. Schimke (1990). Cell-line specific differences
in the control of cell cycle progression in the absence of mitosis. Proc. Natl. Acad.
Sci. USA 87: 9553-9557.
Lane, D. P. (1992). p53, guardian of the genome. Nature 358: 15-16.
Lane, D. P., and L. V. Crawford (1979). T antigen is bound to a host protein in SV40-
transformed cells. Nature 278: 261-263.
Lasek, W., M. Sora, A. Wankowicz, and M. Jakobisiak (1995). Combination of
immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates
antileukemic effect and reduces toxicity in a L1210 leukemia model in mice. Cancer
Lett. 89(1): 137-143.
Lejeune, F., D. Lienard, A. Eggermont, H. Schraffordt Koops, F. Rosenkaimer, J.
Gerain, J. Klaase, B. Kroon, J. Vanderveken, and P. Schmitz (1994). Rationale for
using TNF alpha and chemotherapy in regional therapy of melanoma. J. Cell
Biochem. 56(1): 52-61.
Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88:
323-331.
Li, R., and A. W. Murray (1991). Feedback control of mitosis in budding yeast. Cell
66: 519-531.
Li, Y., and R. Benezra (1996). Identification of a human mitotic checkpoint gene:
hsMAD2. Science 274: 246-248.
Lin, J., J. Chen, B. Elenbaas, and A. J. Levine (1994). Several hydrophobic amino
acids in the p53 amino-terminal domain are required for transcriptional activation,
binding to mdm-2, and the adenovirus E1B 55-kD protein. Genes Dev. 8: 1235-1246.
Linke, S. P., K. C. Clarkin, A. DiLeonardo, A. Tsou, and G. M. Wahl (1996). A
reversible, p53-dependent GO/G1 cell cycle arrest induced by ribonucleotide
depletion in the absence of detectable DNA damage. Genes Dev. 10: 934-947.
Linzer, D. I. J., and A. J. Levine (1979). Characterization of a 54K dalton cellular SV40
tumor antigen in SV40 transformed cells. Cell 17: 43-52.
Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty (1992).
Altered cell cycle arrest and gene amplification potential accompany loss of wild-
type p53. Cell 70: 923-935.
Long, B. H., and C. R. Fairchild (1994). Paclitaxel inhibits progression of mitotic cells
to G1 phase by interference with spindle formation without affecting other
microtubule functions during anaphase and telophase. Cancer Res. 54: 4355-4361.
Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman (1993a). p53-dependent
apoptosis modulates the cytoxicity of anticancer agents. Cell 74: 957-967.
Lowe, S. W. (1995). Cancer therapy and p53. Curr. Opin. Oncol. 7(6): 547-553.
Lowe, S. W., S. Bodis, N. Bardeesy, A. McClatchey, L. Remington, H. E. Ruley, D. E.
Fisher, T. Jacks, J. Pelletier, and D. E. Housman (1994c). Apoptosis and the
prognostic significance of p53 mutation. Cold Spring Harbor Symp. Quant. Biol. 59:
419-426.
Lowe, S. W., S. Bodis, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, D. E.
Housman, and T. Jacks (1994a). p53 status and the efficacy of cancer therapy in vivo.
Science 266: 807-810.
Lowe, S. W., T. Jacks, D. E. Housman, and H. E. Ruley (1994b). Abrogation of
oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc.
Natl. Acad. Sci. USA 91: 2026-2030.
Lowe, S. W., E. S. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks (1993b). p53 is
required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
Lu, H., and A. J. Levine (1995). Human TAF31 protein is a transcriptional
coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92: 5154-5158.
Lutzker, S., and A. J. Levine (1996). A functionally inactive p53 protein in
embryonal carcinoma cells is activated by DNA damage or cellular differentiation.
Nat. Med. 2: 804-810.
Mack, D. H., J. Vartikar, J. M. Pipas, and L. A. Laimins (1993). Specific repression of
TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature
363: 281-283.
Malkin, D., F. P. Li, L. C. Strong, J. F. J. Fraumeni, C. E. Nelson, D. H. Kim, J. Kassel,
M. A. Gryka, F. Z. Bischoff, M. A. Tainsky, and S. H. Friend (1990). Germline p53
mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
Science 250: 1233-1238.
Manthey, C., M. Brandes, P. Perera, and S. Vogel (1992). Taxol increases steady-state
levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation
in murine macrophages. J. Immunol. 149: 2459-2465.
McCurrach, M. E., T. M. Connor, C. M. Knudson, S. J. Korsmeyey, and S. W. Lowe
(1997). Bax-deficiency promotes drug resistance and oncogenic transformation by
attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 94: 2345-2349.
Meek, D. (1994). Post-translational modification of p53. Semin. Cancer Biol. 5: 203-
210.
Minn, A. J., L. H. Boise, and C. B. Thompson (1996). Expression of Bcl-xL and loss of
p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle
damage. Genes Dev. 10: 2621-2631.
Miyashita, T., and J. C. Reed (1995). Tumor suppressor p53 is a direct transcriptional
activator of the human bax gene. Cell 80: 293-299.
Nacht, M., A. Strasser, Y. R. Chan, A. W. Harris, M. Schlissel, R. T. Bronson, and T.
Jacks (1996). Mutations in the p53 and SCID genes cooperate in tumorigenesis.
Genes Dev. 10: 2055-2066.
National Cancer Institute (1983). Clinical brochure: taxol (NSC 125973). Bethesda,
MD.
Nicolaou, K. C., Z. Yang, J. J. Liu, H. Ueno, P. G. Nantermet, R. K. Guy, C. F.
Claiborne, J. Renaud, E. A. Couladouros, and K. Paulvannan (1994). Total synthesis
of taxol. Nature 367: 630-634.
Nogales, E., S. G. Wolf, I. A. Khan, R. F. Luduena, and K. H. Downing (1995).
Structure of tubulin at 6.5 A and location of the taxol binding site. Nature 375: 424-
427.
Okamoto, K., and D. Beach (1994). Cyclin G is a transcriptional target of the p53
tumor suppressor protein. EMBO 13: 4816-4822.
Oltvai, Z., and S. J. Korsmeyer (1994). Checkpoints of dueling dimers foil death
wishes. Cell 79: 189-192.
Owellen, R. J., C. A. Hartke, R. M. Dickerson, and F. O. Hains (1976). Inhibition of
tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer
Res. 36: 1499-1502.
Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein (1997). A model for
p53-induced apoptosis. Nature 389: 300-305.
Rao, S., S. B. Horwitz, and I. Ringel (1992). Direct photoaffinity labeling of tubulin
with taxol. J. Natl. Cancer Inst. 84: 785-788.
Reiss, M., D. E. Brash, T. Munoz-Antonia, J. A. Simon, A. Ziegler, V. F. Velluxxi,
and Z. L. Zhou (1992). Status of the p53 tumor suppressor gene in human squamous
carcinoma cell lines. Oncol. Res. 4(8-9): 349-357.
Rieder, C. L., and R. E. Palazzo (1992). Colcemid and the mitotic cycle. J. Cell Sci. 102:
387-392.
Riondel, J., M. Jacrot, F. Picot, H. Beriel, C. Mouriquand, and P. Potier (1986).
Therapeutic response to taxol of six human tumors xenografted into nude mice.
Cancer Chemother. Pharmacol. 17: 137-142.
Roberts, R. T., K. A. Farr, and M. A. Hoyt (1994). The Saccharomyces cerevisiae
checkpoint gene BUB1 encodes a novel protein kinase. Mol. Cell. Biol. 14: 8282-8291.
Rose, W. C. (1993). Taxol-based combination chemotherapy and other in vivo
preclinical antitumor studies. Mon. Natl. Cancer Inst. 15: 47-53.
Rosell, R., J. L. Gonzalez-Larriba, V. Alberoia, F. Molina, M. Monzo, D. Benito, J. M.
Perez, and J. M. de Anta (1995). Single-agent paclitaxel by 3-hour infusion in the
treatment of non-small cell lung cancer: links between p53 and K-ras gene status and
chemosensitivity. Semin. Oncol. 22: 12-18.
Rowan, S., R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K. H. Vousden
(1996). Specific loss of apoptotic but not cell-cycle arrest function in a human tumor
derived p53 mutant. EMBO J 15: 827-838.
Rowinsky, E., and R. Donehower (1995). Drug Therapy: Paclitaxel (Taxol). New
Engl. J. Med. 332(15): 1004-1014.
Rowinsky, E. K., L. A. Cazenave, and R. C. Donehower (1990). Taxol: a novel
investigational antimicrotubule agent. J. Natl. Cancer Inst. 82: 1247-1259.
Rudner, A. D., and A. W. Murray (1996). The spindle assembly checkpoint. Curr.
Opin. Cell Biol. 8: 773-780.
Rusch, V., D. Klimstra, E. Venkatraman, J. Oliver, N. Martini, R. Gralla, M. Kris, and
E. Dmitrovsky (1995). Aberrant p53 expression predicts clinical resistance to
cisplatin-based chenotherapy in locally advanced non-small cell lung cancer. Cancer
Res. 55: 5038-5042.
Sabbatini, P., J. Lin, A. J. Levine, and E. White (1995). Essential role for p53-mediated
transcription in ElA-induced apoptosis. Genes Dev. 9: 2184-2192.
Schiff, P. B., J. Fant, and S. B. Horwitz (1979). Promotion of microtubule assembly in
vitro by taxol. Nature 277: 665-667.
Schiff, P. B., and S. B. Horwitz (1980). Taxol stabilizes microtubules in mouse
fibroblast cells. Proc. Natl. Acad. Sci. USA 77(3): 1561-1565.
Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L.
Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski, and
A. Ashkenazi (1997). Control of TRAIL-induced apoptosis by a family of signaling
and decoy receptors. Science 277: 818-821.
Shieh, S. Y., M. Ikeda, Y. Taya, and C. Prives (1997). DNA damage-induced
phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
Sidransky, D., A. Von Eschenbach, Y. C. Tsai, P. Jones, I. Summerhayes, F. Marshall,
M. Paul, P. Green, S. R. Hamilton, P. Frost, and B. Vogelstein (1991). Identification
of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709.
Siliciano, J. D., C. E. Canman, Y. Taya, K. Sakaguchi, E. Appella, and M. B. Kastan
(1997). DNA damage induces phosphorylation of the amino terminus of p53. Genes
Dev. 11: 3471-3481.
Smith, M. L., I. Chen, Q. Zhan, I. Bae, C. Chen, T. M. Gilmer, M. B. Kastan, P. M.
O'Connor, and A. J. Fornace (1994). Interaction of the p53-regulated protein Gadd45
with proliferating cell nuclear antigen. Science 266: 1376-1380.
Soussi, T., A. Begue, M. Kress, D. Stehelin, and P. May (1988). Nucleotide sequence
of a cDNA encoding the chicken p53 nuclear oncoprotein. Nuc. Acid Res. 16(23):
11383.
Soussi, T., C. Caron de Fromental, M. Mechali, P. May, and M. Kress (1987). Cloning
and characterization of a cDNA from Xenopus laevis coding for a protein
homologous to human and murine p53. Oncogene 1: 71-78.
Spriggs, D., and S. Yates (1992). Cancer chemotherapy: experiences with TNF
administration in humans. Tumor necrosis factors: their emerging role in
medicine. New York, Raven Press. 383-405.
Sternberg, C. N., P. P. Sordillo, and E. Cheng (1987). Evaluation of new anticancer
agents against human pancreatic carcinomas in nude mice. Am. J. Clin. Oncol. 10:
219-221.
Stewart, N., G. G. Hicks, F. Paraskevas, and M. Mowat (1995). Evidence for a second
cell cycle block at G2/M by p53. Oncogene 10: 109-115.
Takahashi, T., M. Nau, I. Chiba, M. Birrer, R. K. Rosenberg, M. Vinocour, M. Levitt,
H. Pass, A. F. Gazdar, and J. D. Minna (1989). p53: a frequent target for genetic
abnormalities in lung cancer. Science 246: 491-494.
Taylor, S. S., and F. McKeon (1997). Kinetochore localization of murine Bubl is
required for normal mitotic timing and checkpoint response to spindle damage.
Cell 89: 727-735.
Thigpen, J. T., J. Blessing, H. Ball, S. J. Hummel, and R. J. Barrett (1994). Phase II trial
of taxol in patients with progressive ovarian carcinoma after platinum-based
chemotherapy: a gynecologic oncology group study. J. Clin. Oncol. 12: 1748-1753.
Thut, C., J. L. Chen, R. Klemm, and R. Tijan (1995). p53 transcriptional activation
mediated by coactivators TAFII40 and TAFII60. Science 267: 100-104.
Tishler, R. B., D. M. Lamppu, S. Park, and B. D. Price (1995). Microtubule-active
drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally
active p53. Cancer Res. 55(24): 6021-6025.
Vasquez, R. J., B. Howell, A. M. Yvon, P. Wadsworth, and L. Cassimeris (1997).
Nanomolar concentrations of nocodazole alter microtubule dynamic instability in
vivo and in vitro. Mol. Biol. Cell 8: 973-985.
Vogel, S. N., J. M. Carboni, and C. L. Manthey (1995). Paclitaxel, a mimetic of
bacterial lipopolysaccharide (LPS) in murine macrophages. Taxane anticancer
agents. New York, American Chemical Society. 162-172.
Vogelstein, B., and K. Kinzler (1992). p5 3 function and dysfunction. Cell 70: 523-526.
Wagner, A. J., J. M. Kokontis, and N. Hay (1994). Myc-mediated apoptosis requires
wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to
induce p21 WAF1/CIP1. Genes Dev. 8: 2817-2830.
Wahl, A., K. Donaldson, C. Fairchild, F. Lee, S. A. Foster, G. W. Demers, and D. A.
Galloway (1996). Loss of normal p53 function confers sensitization to Taxol by
increasing G2/M arrest and apoptosis. Nat. Med. 2(1): 72-79.
Wang, Y., and C. Prives (1995). Increased and altered DNA binding of human p53 by
S and G2/M but not G1 cyclin-dependent kinases. Nature 376: 88-91.
Wu, G. S., T. F. Burns, E. R. McDonald, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D.
Gan, J. Y. Zhou, R. Muschel, S. R. Hamilton, N. B. Spinner, S. Markowitz, G. Wu,
and W. S. El-Deiry (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated
death receptor gene. Nat. Genet. 17: 141-143.
Wu, G. S., and W. S. El-Deiry (1996). p53 and chemosensitivity. Nat. Med. 2(3): 255-
256.
Xiao, H., A. Pearson, B. Coulombe, R. Truant, S. Zhang, J. L. Regier, S. J. Triezenberg,
D. Reinberg, O. Flores, C. J. Ingles, and J. Greenblatt (1994). Binding of basal
transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol.
Cell. Biol. 14: 7013-7024.
Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach (1993). p21
is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
Yeargin, J., J. Cheng, A. L. Yu, R. Gjerset, M. Bogart, and M. Haas (1993). p53
mutation in acute lymphoblastic leukemia is of somatic origin and is stable during
establishment of T cell acute lymphoblastic leukemia cell lines. J. Clin. Invest. 91:
211-217.
Yin, C., C. M. Knudson, S. J. Korsmeyer, and T. Van Dyke (1997). Bax suppresses
tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640.
Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren (1991).
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by
interleukin-6. Nature 352: 345-347.
Zambetti, G. P., J. Bargonneti, K. Walker, C. Prives, and A. J. Levine (1992). Wild-
type p53 mediates positive regulation of gene expression through a specific DNA
sequence element. Genes Dev. 6: 1143-1152.
Chapter 2
Induction of p53-dependent and p53-independent apoptosis
by the chemotherapeutic paclitaxel
The experiments described in this chapter were performed with the assistance of
Scott W. Lowe (Cold Spring Harbor Laboratory, NY); Edward J. Licitra, and Jun O.
Liu (Center for Cancer Research, M.I.T.).
Introduction
Most chemotherapeutic agents were identified by virtue of their cytotoxicity against
tumor cell lines. The basis for their mechanism of action remains poorly
understood, but has been thought to be due to inhibiting tumor cell growth.
Recently, the realization that many of these agents induce apoptosis, a genetically
determined form of cell death, has forced a reevaluation of the mechanisms by
which cytotoxic agents inhibit tumor growth. These studies have identified
correlations between drug responsiveness and tumor genotype (Lowe et al., 1993a;
Lowe et al., 1994; rev. in Biedler 1992; Reed 1995). Consequently, a further
understanding of how tumor-specific mutations affect treatment efficacy may
ultimately provide a more rational basis for choice of anticancer regimen.
Mutations in the p53 tumor suppressor gene have recently been shown to have an
impact on the clinical course of human tumors. Indeed, patients harboring tumors
with p53 mutations often have a worse prognosis than those harboring tumors with
wild-type p53 (rev. in Lowe 1995) and in several instances, p53 mutations have been
associated with drug-resistant tumors (Bergh et al., 1995; Goh et al., 1995; Rusch et
al., 1995; Aas et al., 1996). Consistent with these clinical findings, inactivation of p53
can promote tumorigenesis and lead to drug resistance in experimental settings.
The p53 gene encodes a transcription factor that can regulate cell proliferation and
survival by modulating transcription of downstream target genes, inducing either
G1 arrest or apoptosis (Clarke et al., 1993; El-Deiry et al., 1993; Harper et al., 1993;
Lowe et al., 1993a; Lowe et al., 1993b). p53 is activated to promote G1 arrest or
apoptosis by several stimuli, the most well-characterized being DNA damage. Many
known anticancer agents cause DNA damage, presumably leading to p53-dependent
apoptosis. Inactivation of the apoptotic response provides an attractive explanation
to account for the poor responsiveness of p53 mutant tumors to these agents. Thus,
identifying chemotherapeutic agents that act independently of the p53 pathway is of
fundamental importance.
Paclitaxel, a drug used for cancer therapy, is derived from the Pacific yew tree (Taxus
brevifolia), and was initially considered promising because of its cytotoxic activity
against several tumor cell lines (Wani et al., 1971; Douros and Suffness 1978).
Subsequent studies demonstrated that paclitaxel was effective against a variety of
murine tumors and human xenografts (National Cancer Institute, 1983; Riondel et
al., 1986; Riondel et al., 1988), as well as advanced human carcinomas refractory to
traditional chemotherapy (rev. in Rowinsky and Donehower 1995). Paclitaxel
promotes the assembly of microtubules in vitro (Schiff et al., 1979). Consequently,
the cytotoxic effect of the drug in tissue culture can be attributed to its ability to
stabilize cellular microtubules and thus inhibit formation of the mitotic spindle
(Schiff and Horwitz 1980). However, in addition to its microtubule-stabilizing
activity, paclitaxel also stimulates the lipopolysaccharide (LPS) signalling pathway in
murine macrophages, resulting in secretion of the cytokines interleukin-1li (IL-1~)
and tumor necrosis factor-a (TNF-o) (Ding et al., 1990; Bogdan and Ding 1992;
Manthey et al., 1992; Carboni et al., 1993). This effect is independent of its ability to
stabilize microtubules, as some derivatives of paclitaxel retain microtubule-
stabilizing activity but do not stimulate cytokine secretion (Manthey et al., 1993;
Burkhart et al., 1994). Interestingly, TNF-a itself can induce apoptosis and has well-
documented anticancer activity (reviewed in Beyaert 1994; Hieber and Heim 1994).
In human macrophages, paclitaxel alone has not been shown to induce TNF-a or IL-
l f secretion, but it does enhance production of these cytokines when applied in
conjunction with LPS (Allen et al., 1993).
Since p53 promotes apoptosis following DNA damage, it might be expected that a
microtubule-stabilizing drug such as paclitaxel would have p53-independent effects.
Indeed, several of the human xenografts that responded to paclitaxel in preclinical
trials are documented to have p53 mutations (National Cancer Institute, 1983; Baker
et al., 1989; Reiss et al., 1992; Rose 1993; Joschko et al., 1994). However, paclitaxel-
induced cell cycle arrest is compromised in murine fibroblasts lacking p53,
suggesting that p53 may in fact contribute to paclitaxel's biological effects (Wahl et
al., 1996). Furthermore, in an ovarian teratocarcinoma cell line, paclitaxel induced
apoptosis to a greater extent in cells with intact p53 function than in cells in which
p53 was inactivated through expression of human papilloma virus type 16 E6
protein (Wu and El-Deiry 1996). Thus, there is an apparent discrepancy between the
effects of p53 status on the response of cells to paclitaxel in vivo versus in vitro. In
order to characterize the effectiveness of paclitaxel against transformed cells, we
sought to determine the relationship between paclitaxel response and p53 status.
Methods
Cells and cell culture. p53 +/+ and p53 -/- mouse embryonic fibroblasts (MEFs) were
derived from 13.5 day old embryos and used at early passage (Jacks et al., 1994). p53
+/+ and p53 -/- MEF clones stably expressing ElA and T24 H-ras were generated by
calcium phosphate coprecipitation as previously described (Lowe et al., 1993a). The
RAW 264.7 cell line was a gift from Dr. Gerald Wogan (M.I.T., Division of
Toxicology, Cambridge, MA). All cells were maintained in Dulbeccos' modified
Eagle's medium containing 10% fetal bovine serum supplemented with penicillin
and streptomycin.
Dose-response assays. Exponentially growing fibroblasts were plated at a density of 8
. 104 cells per 34 mm well for untransformed MEFs and 1.5 - 105 cells per 34 mm well
for transformed MEFs. Twenty-four hours after plating, growth medium was
replaced with fresh medium containing the appropriate concentration of
recombinant murine tumor necrosis factor-a (TNF-a) (Boehringer Mannheim),
paclitaxel or cephalomannine (provided by the National Cancer Institute, Drug
Synthesis and Chemistry Branch). Cell viability was determined after a 48 hour
treatment by pooling adherent and nonadherent cells and measuring uptake of
propidium iodide as determined by FACScan.
Conditioned medium assay. RAW 264.7 murine macrophages were plated at a
density of 7.5 - 106 cells per 100 mm dish, allowed to adhere, and treated with 30 AiM
paclitaxel or cephalomannine for 24 hours. The macrophage growth medium was
collected, filtered, and applied to wells of fibroblasts ( 8 - 104 cells per 34 mm well for
untransformed MEFs; 1.5 • 105 cells per 34 mm well for ElA-Ras expressing MEFs).
Fibroblasts were grown in the conditioned medium for 24 hours and then analyzed
for cell viability by propidium iodide uptake. For anti-TNF-a experiments,
macrophage growth medium was incubated with monoclonal hamster anti-mouse
TNF-a (Genzyme) at concentrations of 0.1, 0.2 and 1 gg/ml of conditioned media for
2 hours at 37°C prior to addition to fibroblasts. The control antibody was
monoclonal hamster anti-mouse CD3 used at a concentration of 1 jig/ml of
conditioned media (Pharmingen).
Apoptosis assay. ElA-Ras expressing MEFs were plated onto poly-D-lysine coated
coverslips at a density of 1.5 - 105 cells per 34 mm well. Twenty-four hours after
plating, growth medium was replaced with fresh medium containing 10 gg/ml
recombinant TNF-a. After 15 hours of treatment, cells were fixed in 2%
paraformaldehyde/phosphate-buffered saline (PBS) for 15 minutes, washed with
PBS, permeabilized for 15 minutes in 0.25% Triton X-100/PBS, and washed again
with PBS. Cells were then stained for 5 minutes with 4,6-diamidino-2-phenylindole
(DAPI) at a concentration of 1 jgg/ml PBS. Coverslips were mounted on glass slides
with Mowiol and analyzed via fluorescence microscopy.
Results
Induction of p53-dependent apoptosis by paclitaxel
We chose to examine paclitaxel response in a well-characterized system consisting of
wild type and p53-deficient primary mouse embryonic fibroblasts (MEFs)
transformed with the adenovirus-5-E1A oncogene and the T24-activated-H-ras allele
(Lowe et al., 1993a). These highly transformed cells differ in p53 genotype but are
otherwise genetically similar, thus constituting a good model system in which to
determine how p53 status affects response to chemotherapeutic agents (e.g., see
Lowe et al., 1993a).
The viability of ElA-Ras transformed, wild-type and p53-deficient MEFs and
untransformed control MEFs treated with paclitaxel is summarized in Fig. 2.1. Cells
were treated with the indicated concentration of paclitaxel for 48 hours, then
analyzed for viability by propidium iodide exclusion. In the transformed fibroblast
populations, paclitaxel treatment led to preferential killing of cells containing wild-
type p53. p53 +/+, ElA-Ras transformed MEFs had an IC50 of 75 nM, while the IC50
of their p53 -/- counterparts was >30 gM. Death occurred by induction of the
apoptotic pathway, as determined by condensed chromatin and nuclear
fragmentation visible in cells stained with DAPI (data not shown). The viability of
untransformed MEFs was largely unaffected by exposure to paclitaxel at the
concentrations tested, although p53 -/- MEFs did show a slight decrease in viability,
as has been observed previously (Hawkins et al., 1996; Wahl et al., 1996).
Macrophage-mediated killing of p53-deficient tumor cells
The observation that paclitaxel induced p53-dependent apoptosis in transformed
cells was unexpected, since paclitaxel was effective against p53 mutant tumors in
FIG. 2.1
Induction of p53-dependent apoptosis in transformed cells by paclitaxel.
Viability of p53 +/+ untransformed fibroblasts, p53 -/- untransformed fibroblasts,
p53 +/+ ElA-Ras expressing fibroblasts, and p53 -/- ElA-Ras expressing fibroblasts
is shown following paclitaxel treatment. Cells were grown in paclitaxel-containing
media at the indicated concentrations for 48 hours, harvested, and analyzed for
viability as determined by propidium iodide exclusion using flow cytometry.
Treatment of cells with equal amounts of carrier alone (ethanol) had no effect on
viability (not shown). Data shown represent the analysis of 3 experiments, with
error bars indicated.
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preclinical studies (National Cancer Institute, 1983; Baker et al., 1989; Reiss et al.,
1992; Rose 1993; Joschko et al., 1994). This discrepancy could be resolved if, in
addition to its ability to directly induce p53-dependent apoptosis, paclitaxel also acted
through an indirect mechanism that required a tumor microenvironment. In this
regard, the ability of paclitaxel to stimulate release of cytokines from tumor-
associated macrophages provides a potential mechanism.
To determine whether paclitaxel could induce secretion of a cytotoxic cytokine from
macrophages, we utilized an in vitro tissue culture assay which recapitulated events
that might occur in an in vivo tumor setting. We included as a control the
paclitaxel derivative cephalomannine, which retains the ability to stabilize
microtubules but does not induce cytokine secretion (Burkhart et al., 1994). Cells
from the murine macrophage cell line RAW 264.7 were exposed to 30 jgM paclitaxel
or 30 gM cephalomannine for 24 hours. This concentration of paclitaxel is
comparable to plasma levels of paclitaxel following a standard therapeutic dose
(Innocenti et al., 1995). The media from the treated macrophages was then collected,
filtered, and applied to p53 -/- ElA-Ras expressing MEFs. After 24 hours of
incubation with the macrophage-conditioned media, the transformed MEFs were
assayed for viability (Fig. 2.2). As would be predicted from the results presented in
Fig. 2.1, treating p53 -/- cells directly with 30 jiM paclitaxel led to only a modest loss
of viability. However, exposing these cells to conditioned media from macrophages
treated with 30 jiM paclitaxel caused a sharp decrease in viability. Importantly,
incubation of the cells in media from macrophages treated with cephalomannine
did not cause a decrease in viability beyond that observed following direct paclitaxel
treatment. These data suggest that macrophages exposed to paclitaxel release a
soluble factor into the media which induces apoptosis in p53 -/- transformed
fibroblasts.
FIG. 2.2
Effects of macrophage-conditioned media on p53 -/- transformed cells.
Murine macrophages (RAW 264.7) were treated with 30 gM paclitaxel or 30 jiM
cephalomannine for 24 hours. Macrophage-conditioned media was collected,
filtered, and applied to ElA-Ras p53 -/- fibroblasts. After 24 hours, viability of
fibroblasts was determined using propidium iodide exclusion and flow cytometry.
Viability of ElA-Ras p53 -/- fibroblasts was also determined following treatment
with 30 gM paclitaxel directly, and following incubation in conditioned medium
from untreated RAW 264.7 cells. Data shown represent the analysis of 3
experiments, with error bars indicated.
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TNF-a release from macrophages
TNF-a is a likely candidate for the cytotoxic factor secreted by paclitaxel-treated
macrophages, since earlier studies have shown both that paclitaxel induces secretion
of TNF-a (Ding et al., 1990) and that TNF-a can promote apoptosis (Beyaert 1994).
To test whether TNF-a was the cytotoxic factor present in the conditioned media,
RAW 264.7 macrophages were treated with paclitaxel for 24 hours, and the
conditioned media was then collected and incubated for 1 hour with a monoclonal
antibody to TNF-x. The MEFs were then grown in the macrophage-conditioned
media for 24 hours and subsequently assayed for viability. As shown in Fig. 2.3,
preincubation of the conditioned media with 0.1 gg/ml of an anti-TNF-a
monoclonal antibody protected a large portion of the cell population from death.
Incubation with higher concentrations of antibody restored the viability of the p53
-/- transformed MEFs to near untreated levels. However, preincubation of the
conditioned media with a control monoclonal antibody against CD3 had no effect on
viability. These data strongly suggest that the cytotoxic factor released by
macrophages upon paclitaxel treatment is TNF-a.
Direct induction of apoptosis by TNF-a
To prove that TNF-c is capable of inducing p53-independent apoptosis, we
examined the response of ElA-Ras transformed MEFs when treated directly with
TNF-ac (Fig. 2.4a). Untransformed and ElA-Ras expressing p53 +/+ and p53 -/- MEFs
were treated with TNF-a at various concentrations for a 48 hour period and then
assayed for viability. Exposure to TNF-a led to significant cytotoxicity in all ElA-Ras
expressing cells, independent of their p53 status. Cells died by apoptosis, as
determined morphologically and by nuclear staining with DAPI (Fig. 2.4b) The
viability of untransformed MEFs was unaffected by TNF-a treatment (Fig. 2.4a). The
ability of TNF-a to induce death in ElA-Ras p53 -/- tumor cells supports the idea
that paclitaxel acts via TNF-a secretion in vivo.
FIG. 2.3.
Protection from apoptosis by anti-TNF-a antibody.
Conditioned media from paclitaxel-treated macrophages was incubated with
monoclonal anti-TNF-a or anti-CD3 antibody, then applied to ElA-Ras p53 -/-
fibroblasts. Viability of fibroblasts was determined after 24 hours using propidium
iodide staining and flow cytometry. Data shown represent the analysis of 3
experiments, with error bars indicated.
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FIG. 2.4
Induction of p53-independent apoptosis by TNF-a.
(A) Viability of p53 +/+ untransformed fibroblasts, p53 -/- untransformed
fibroblasts, p53 +/+ ElA-Ras expressing fibroblasts, and p53 -/- ElA-Ras expressing
fibroblasts following TNF-a treatment. Cells were grown in media containing TNF-
a at the indicated concentrations for 48 hours, harvested, and analyzed for viability
as determined by propidium iodide exclusion using flow cytometry. Data shown
represent the analysis of 3 experiments, with error bars indicated.
(B) Induction of apoptosis by TNF-a in ElA-Ras p53 -/- fibroblasts. Cells were
treated with TNF-a (10 ng/ml) for 15 hours, at which time a significant fraction had
undergone apoptosis. Cells were then fixed, stained with the nuclear stain 4,6-
diamidino-2-phenylindole (DAPI), and examined using fluorescence microscopy.
Arrows indicate apoptotic nuclei, with condensed, brightly staining chromatin.
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Discussion
The present study describes how the chemotherapeutic agent paclitaxel may use a
novel mode of action against tumors. Like traditional antineoplastic therapies such
as adriamycin and gamma-irradiation (Lowe et al., 1993a; Lowe et al., 1994),
paclitaxel can act directly on the target tumor cell and induce apoptosis via a p53-
dependent pathway. However, unlike these other treatments, paclitaxel also has the
potential to act indirectly against tumor cells by stimulating macrophages to secrete
the cytokine TNF-a. This secondary effect could circumvent the issue of the p53
genotype of the target cell, because we have demonstrated that TNF-a induces
apoptosis in transformed cells irrespective of their p53 status.
Direct induction of p53-dependent apoptosis
Given that p53's function is understood primarily from its role in the DNA damage
response pathway, it is interesting that paclitaxel, a microtubule stabilizing drug,
should elicit a p53-dependent response. Data from untransformed fibroblasts also
suggest a p53 connection, as MEFs lacking p53 have decreased viability after
paclitaxel treatment (Hawkins et al., 1996; Wahl et al., 1996). Also, experiments in
which untransformed fibroblasts were treated with the microtubule-destabilizing
agents nocodazole and colcemid indicate a possible role for p53 as a mitotic spindle
checkpoint (Cross et al., 1995). It is presently unclear, however, how the state of
cellular microtubules influences the p53 pathway.
The extreme sensitivity of p53 +/+ ElA-Ras transformed cells to paclitaxel is
striking, with apoptotic cells observed at paclitaxel concentrations as low as 10 nM.
In untransformed fibroblasts, low concentrations of paclitaxel induce mitotic block
not by increasing tubulin polymerization, but by suppressing the dynamic growth
and shrinkage of the mitotic spindle (Jordan et al., 1993). Interestingly, this
mechanism is identical to that of the microtubule destabilizing agent vinblastine,
suggesting that in untransformed cells, both classes of antimitotic drugs share a
common antiproliferative mechanism (Jordan et al., 1991; Jordan et al., 1993). A
common pathway may also be functioning in transformed cells treated with
antimitotic drugs, since the microtubule-destabilizing agent vincristine, which is
structurally similar to vinblastine, also induces p53-dependent apoptosis in ElA-Ras
transformed fibroblasts (data not shown). Thus, drugs which stabilize or destabilize
microtubules both may lead to p53-dependent cell cycle arrest or apoptosis,
depending on the cellular context.
TNF-a secretion and p53-independent apoptosis
Paclitaxel also has the ability to induce TNF-a release from murine macrophages
(Ding et al., 1990). Other studies suggest that TNF-a-induced apoptosis proceeds
through a complex of molecules that link the trimeric TNF-a receptor to several
downstream effectors (Baker and Reddy 1996). In this study, we observe that p53 is
dispensable for TNF-a-induced apoptosis, since TNF-a treatment triggered apoptosis
in ElA-Ras transformed fibroblasts in a p53-independent manner. Therefore, our
data suggest that the p53 protein is not a component of the TNF-ax apoptotic
pathway.
The observation that TNF-a can induce p53-independent apoptosis in transformed
cells would suggest that TNF-a itself could be an effective antineoplastic treatment,
particularly against tumors which have sustained p53 mutations. TNF-( has long
been recognized as an agent capable of inducing marked tumor regression, and has
undergone considerable testing against tumors in patients and animal models.
Systemic administration of TNF-a in humans produced severe side effects and was
ineffective against tumors (reviewed in Spriggs and Yates 1992). More recently,
however, local administration of TNF-a alone, or in combination with other drugs
and cytokines, was effective at inhibiting tumor growth with minimal side effects in
both tumor models and human patients (Baisch et al., 1990; Asher et al., 1991;
Lejeune et al., 1994; Lasek et al., 1995; Lasek et al., 1996). These results lend support
to further testing of TNF-a as an anticancer agent.
Therapeutic effectiveness of paclitaxel
This study supports prior observations that paclitaxel can promote the release of
TNF-a from murine macrophages, and additionally shows that the secreted
cytokine can efficiently induce apoptosis in p53 -/- ElA-Ras transformed MEFs. We
suggest that this mode of action contributes to the activity of paclitaxel in murine
tumor model systems, as solid tumors are often infiltrated by macrophages
(Mantovani et al., 1992). Accordingly, our study predicts that paclitaxel should be
effective against tumors with inactivated p53. We have attempted to demonstrate
this by treating tumors generated in nude mice from ElA-Ras transformed cells;
however, we found that paclitaxel was not measurably active against such tumors,
regardless of their p53 genotype (data not shown). However, data obtained from
testing of paclitaxel in other tumor models support our prediction: paclitaxel was
effective in preclinical testing against the human tumors CX-1 (colon), A431 (vulva),
and FaDu (hypopharynx) when xenografted into nude mice (National Cancer
Institute, 1983; Rose 1993; Joschko et al., 1994), all of which are documented to
contain p53 mutations (Baker et al., 1989; Reiss et al., 1992). Additionally, paclitaxel
was effective against numerous other tumor xenografts (Nicoletti et al., 1993; Rose
1993; Joschko et al., 1994; Milross et al., 1995), few of which have been screened for
their p53 status but at least some of which are likely to contain mutated p53.
It will be important to establish whether in human patients, paclitaxel activity is
contingent upon macrophage stimulation and subsequent cytokine release. The
activation of the LPS pathway by paclitaxel alone has only been documented in
mouse macrophages, and could represent a species difference (Allen et al., 1993;
Ding et al., 1993). The observation that paclitaxel can enhance TNF-a and IL-1B gene
expression in the presence of LPS might suggest that paclitaxel does activate the LPS
pathway in human macrophages, but only in conjunction with a second signal
(Allen et al., 1993). How the p53 status of human tumors determines their
responsiveness to paclitaxel is unclear, but it is noteworthy that paclitaxel is effective
in treating breast cancer, a tumor type with a high frequency of p53 mutations
(Ozbun and Butel 1995). Left unexplained is the apparent selectivity of paclitaxel,
which is effectively used to treat ovarian and breast cancer, among others. One
might expect that neither the microtubule-based nor the cytokine-based effects
would be specific to tumor tissue type. Based on the present work, one possible
explanation for this apparent selectivity would be that different tumor types have
different degrees of macrophage infiltration.
If paclitaxel acts through a cellular intermediate, then it represents a new mode of
action for chemotherapeutic agents. Moreover, these data suggest that the critical
feature of paclitaxel as an anti-tumor agent may not be its microtubule-stabilizing
activity, but its ability to activate components of the immune system. Therefore,
this aspect of the drug's action should be a focus of efforts to improve its
effectiveness through modification.
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Chapter 3
Characterization of the p53-dependent postmitotic checkpoint
following spindle disruption
Introduction
The proper execution of events in the eukaryotic cell cycle is regulated by a number
of different checkpoints. For example, to ensure stable maintenance of the genome,
cells arrest in G1 or G2 upon detection of DNA damage, providing time for DNA
repair before the initiation of DNA synthesis or entry into mitosis (Elledge 1996).
Other checkpoints function during mitosis to monitor successful assembly of the
spindle and control the initiation of metaphase, thus protecting the cell from
chromosome missegregation (Rudner and Murray 1996). Genes that are required for
cellular arrest at different checkpoints have been identified, demonstrating that each
checkpoint is a genetic pathway activated by specific signals. The inactivation of
checkpoint genes leads to increased mutation rate, chromosome loss, or changes in
ploidy, depending on the genes affected (Paulovich et al., 1997). Interestingly, some
genes that are mutated in human cancers are involved in checkpoint functions,
suggesting that without such controls in place, the resulting genetic damage
predisposes cells to malignancy (Sherr 1996).
The p53 tumor suppressor gene is mutated in over half of all sporadic human
cancers. p53 has an essential role in the G1 checkpoint in response to DNA-
damaging agents such as radiation (Kastan et al., 1991; Kastan et al., 1992; Kuerbitz et
al., 1992). Functional analysis of the p53 protein has shown that it is a transcription
factor with sequence-specific DNA binding activity (Farmer et al., 1992; Kern et al.,
1992; Zambetti et al., 1992). After DNA damage, p53 activates the transcription of
several downstream target genes, including p21, an inhibitor of cyclin-dependent
kinases (CDKs) (El-Deiry et al., 1993). The induction of p21 causes subsequent arrest
in the G1 phase of the cell cycle by binding of cyclin-CDK complexes (Gu et al., 1993;
Harper et al., 1993; Xiong et al., 1993). Additional p53 target genes are likely to
cooperate with p21 in implementing G1 arrest, as p21-deficient mouse cells are only
partially defective in their DNA damage arrest response, while p53-deficient cells are
completely defective (Brugarolas et al., 1995; Deng et al., 1995).
Recently, p53 has been proposed to have an additional, novel function as a
checkpoint at mitosis. Wild-type fibroblasts arrest when the mitotic spindle
assembly is disrupted by the addition of drugs which bind microtubules. However,
studies have shown that p53-deficient fibroblasts fail to arrest under such conditions
but instead undergo a new round of DNA synthesis in the absence of cell division,
becoming polyploid (Cross et al., 1995; Minn et al., 1996; Di Leonardo et al., 1997).
This phenotype is very similar to that observed in yeast strains that have inactivated
spindle assembly checkpoints. S. cerevisiae strains with mutations in the MAD or
BUB genes, which monitor spindle assembly, become polyploid when treated with
spindle inhibitors (Hoyt et al., 1991; Li and Murray 1991). Based on this similarity,
one might conclude that, like the MAD and BUB gene products, p53 monitors
spindle integrity and can thus be termed a mitotic checkpoint. Also, additional data
have suggested that the spindle components themselves may be under p53
regulation, as p53 has been shown to localize to the centrosome (Brown et al., 1994),
and p53 -/- MEFs contain abnormal numbers of centrosomes (Fukasawa et al.,
1996). However, later work has shown that in cells treated with spindle inhibitors,
p53 is neither expressed during mitosis nor required for mitotic arrest (Minn et al.,
1996). Instead, expression of p53 protein occurs only after cells exit mitotic arrest and
progress to an interphase state while still retaining 4N DNA content. These data
argue that p53 does not function as part of a mitotic checkpoint but acts at some
subsequent point in the cell cycle to induce arrest following a defect in M phase.
In this study, we have characterized in greater detail the p53-dependent checkpoint
following disruption of the mitotic spindle with microtubule-destabilizing drugs.
Upon examining the response of wild-type and p53-deficient mouse embryo
fibroblasts to spindle inhibitors, we observed that cells of either genotype underwent
a transient arrest at mitosis and subsequently progressed into a Gl-like state without
ever completing cell division. Wild-type MEFs remained arrested in this state,
while p53 -/- MEFs initiated another round of DNA synthesis. Using time-lapse
videomicroscopy, we were able to define the length of mitotic arrest and establish
precisely the timing of S phase reentry in p53 -/- MEFs after exit from mitotic arrest.
We also demonstrated a requirement for the p53 target gene product, p21, in
executing cell-cycle arrest after spindle disruption. Upon further characterization of
arrested cells, we determined that cells expressed molecular markers associated with
the G1 phase of the cell cycle despite having 4N DNA content. These data
demonstrate that the p53-dependent checkpoint in cells with disrupted mitotic
spindles has strong similarity to the p53-dependent checkpoint in G1 following
DNA damage. Our data suggest that rather than having a novel role as part of a
spindle checkpoint, p53 functions in the G1 phase of the cell cycle and via the same
downstream pathway in murine cells which have sustained either DNA damage or
microtubule disruption.
Methods
Cells and cell culture. p53 +/+ and p53 -/- mouse embryonic fibroblasts (MEFs)
were derived from 13.5 day old embryos and used between passages 3 and 8 (Jacks et
al., 1994). MEFs were maintained in Dulbecco's modified Eagle's medium (DMEM)
containing 10% fetal bovine serum supplemented with penicillin and streptomycin.
For flow cytometry and immunoblot experiments, MEFs were plated at a density of 5
x 105 - 1 x 106 cells per 100 mm dish, 24 h in advance of experiments. Nocodazole
(Sigma) was kept as a 1 mg/ml stock in DMSO. Nocodazole treatment of MEFs was
performed at a concentration of 0.125 gg nocodazole/ml media.
NIH 3T3 cells were obtained from the American Type Culture Collection, and were
grown in DMEM containing 10% calf serum supplemented with penicillin and
streptomycin. For flow cytometry and immunoblot experiments, NIH 3T3 cells
were plated at a density of 5 x 105 cells per 100 mm dish. 24 h after plating, cells were
serum synchronized by washing twice with DMEM, then placing in DMEM plus
0.5% calf serum for 48 h. Nocodazole treatment of NIH 3T3 cells was performed at a
concentration of 0.5 jg nocodazole/ml media.
Flow cytometry. Approximately 1 x 106 cells per 100 mm dish were detached in
0.25% trypsin and washed in phosphate-buffered saline (PBS). Following
centrifugation, cells were resuspended in 0.5 ml cold PBS. Cells were fixed by adding
4.5 ml cold 100% ethanol dropwise to the sample while vortexing gently, and then
placing at -20"C for at least 60 min. After fixation, cells were spun out of ethanol,
washed once with PBS, and resuspended in 20 gg propidium iodide (Sigma) + 200
gg RNAse (Sigma)/ml PBS. Cells were incubated at 37C for 30 min and allowed to
stain for at least 8 h at 4"C. Samples were analyzed for DNA content on a Becton
Dickinson FACScan.
Immunofluorescence. 1 x 105 MEFs were plated onto glass coverslips in a 34 mm
tissue culture well. MEFs were allowed to adhere to coverslips for 24 h, then were
changed into medium with or without nocodazole (0.125 gg/ml) and incubated for
24 h. Bromodeoxyuridine (BrdU) and fluorodeoxyuridine (FdU) (Sigma) were
added to the medium from a 1000x stock solution in H20, for a final concentration of
3 jig BrdU + 0.3 jgg FdU/ml medium; cells were incubated for an additional 4 h.
Coverslips were then fixed in 4% paraformaldehyde/PBS for 20 min at room temp,
washed in PBS, permeabilized for 15 min in 0.25% Triton X-100/PBS, and washed
again with PBS. For BrdU detection, slips were denatured in 1.5 N HCI for 10 min
and washed several times with PBS. Slips were incubated with a murine
monoclonal antibody to BrdU (Becton Dickinson, 1:50 dilution) in 10% goat
serum/PBS for 30 min at 37C. After 2 PBS washes, fluorescein-conjugated anti-
mouse antibody (Jackson Immunoresearch Laboratories, 1:200 dilution) was added
in 10% goat serum/PBS, and slips were incubated for 30 min at 37C. Slips were
washed with PBS and stained for 5 min in 0.2 gg 4,6-diamidino-2-phenylindole
(DAPI; Sigma)/ml PBS. Coverslips were mounted on glass slides with Mowiol and
analyzed via fluorescence microscopy.
Time-lapse videomicroscopy. MEFs were grown on 12 mm glass coverslips as
above. A single coverslip was placed in a dish containing 2 ml HEPES-buffered
DMEM + 10% fetal bovine serum, with or without nocodazole (0.125 gg/ml). Each
coverslip was observed for up to 24 h under a Nikon microscope. Recording was
done by taking one picture frame every 8 seconds using a GYYR TLC2100 time-lapse
VCR. During recording, MEFs were maintained at 37C using a Delta temperature
controller and kept in an environment of 5% CO 2 by bubbling gas across the surface
of the media. Pictures were printed out using a Sony color video printer. All
equipment was obtained from Micro Video Instruments, Inc.
For time-lapse videomicroscopy followed by immunofluorescence, MEFs were
grown on gridded cover slips (Bellco) placed in 34 mm wells, with 1 x 105 MEFs
plated per well. A single square of the grid was followed by time-lapse
videomicroscopy for 18 to 24 h. For BrdU incorporation assays, 2 jil BrdU/FdU
1000x stock solution was added directly to the dish 4 h before the end of the
experiment, for a final concentration of 3 jgg BrdU + 0.3 gg FdU/ml medium. After
recording was complete, the gridded slip was fixed in 4% paraformaldehyde/PBS
and immunofluorescence was performed. The cells which had been recorded on
video were identified during immunofluorescent analysis by locating the same
square of the grid.
Immunoblotting. Whole cell extracts were made by scraping approximately 1 x 106
cells in 200 gl boiling lysis buffer (100 mM NaC1, 10 mM Tris pH 8.0, 1 % SDS).
Lysates were heated at 100"C for 10 min, quick frozen in a dry ice/ethanol bath, and
stored at -80°C. Protein concentration of lysates was determined using a
bicinchoninic acid (BCA) kit (Pierce). For cyclin E, cyclin B1, and p21 immunoblots,
100 jgg of protein was loaded per lane on a 10% (29:1) SDS-PAGE gel. Gels were
electrophoresed at 150 V for 4 h, then transferred to to Immobilon-P membrane
(Millipore) in low MW transfer buffer (25 mM Tris, 190 mM glycine, 20% methanol)
for overnight at 25 V at 4"C. Blots were pre-blocked in 0.01% Tween-20/ PBS (PBS-
T) + 5% dried milk for 1 h at room temp, then probed with primary antibody diluted
in block solution for 1 h at room temp. Antibodies and dilutions were as follows:
cyclin E, Santa Cruz M-20, 1:200 dilution; cyclin B1, Pharmingen GNS-1, 1:200
dilution; p21, Santa Cruz C19-G, 1:100 dilution. Blots were then washed with PBS-T
3 times for 10 min. For p21 detection, blots were put through an additional
incubation step in mouse anti-goat antibody (Jackson Immunoresearch Laboratories,
1:12000) diluted in block solution for 1 h at room temp, followed by 3 washes in PBS-
T. All blots were then incubated in peroxidase-linked secondary antibody
(Amersham, 1:5000 dilution) for 1 h at room temp and washed 3 times in PBS-T.
Blots were developed with ECL reagents and exposed to Kodak X-OMAT 5 film for 1-
20 minutes.
For pRB immunoblots, 350 gg of protein was loaded per lane on a 6% (29:1) SDS-
PAGE gel. Gels were electrophoresed at 20 mAmp overnight, then transferred to
Immobilon-P membrane in high MW transfer buffer (50 mM Tris, 380 mM glycine,
0.1% SDS, 20% methanol) for 14 h at 25 V at 4°C, and for an additional hour at 40 V.
Blots were pre-blocked in 0.03% Tween-20 in 10 mM Tris pH 7.5, 150 mM NaCl
(TBS-T) + 5% dried milk for 1 h at room temp, then probed with primary antibody
diluted in block solution for 1 h at room temp (Pharmingen G3-245, 1:100 dilution).
After 3 10 min washes in TBS-T, blots were incubated in rabbit anti-mouse antibody
(Jackson Immunoresearch Laboratories, 1:14,000) for 1 h at room temp. Blots were
washed 3 times in TBS-T, incubated in peroxidase-linked tertiary antibody
(Amersham, 1:5000 dilution) for 1 h at room temp, and washed 3 times in TBS-T.
Blots were developed as above.
Results
Inappropriate DNA synthesis in nocodazole-treated p53 -/- fibroblasts
Because previous results regarding p53 function at mitosis were contradictory, we
chose to characterize in greater detail the effect of p53 deficiency on cells treated with
spindle inhibitors. To confirm a requirement for p53 following spindle disruption,
wild-type and p53-deficient MEFs were grown in the presence of the microtubule-
destabilizing drug nocodazole. After 24 h of treatment, cells were fixed and stained
with propidium iodide for analysis by flow cytometry (Fig. 3.1A). Wild-type MEFs
treated with nocodazole arrested with primarily a 4N DNA content. A small
subpopulation of wild-type cells that had 8N DNA content was observed, perhaps
reflecting the presence of cycling tetraploid cells in the normal population, which
would be predicted to arrest with 8N DNA content upon spindle disruption. As
described previously, p53 -/- fibroblasts did not arrest with a 4N DNA content upon
drug treatment, but continued through an additional round of S phase to become
8N (Fig. 3.1A; Cross et al., 1995; Minn et al., 1996; Di Leonardo et al., 1997).
In order to examine specifically the fraction of cells capable of S-phase reentry
following nocodazole treatment, cells were treated with nocodazole for 24 h, pulsed
with BrdU for an additional 4 h while still in the presence of drug, and analyzed by
immunofluorescence for anti-BrdU staining (Fig. 3.1B). Untreated wild-type and
p53 -/- MEFs had similar proportions of cells in S phase. After 28 h of nocodazole
treatment, very few BrdU-positive cells were observed in the wild-type MEF
population, consistent with their ability to induce cell cycle arrest after nocodazole
treatment. However, many p53 -/- MEFs incorporated BrdU while in the presence
of nocodazole, indicating that they were able to reenter the cell cycle and initiate
DNA synthesis, despite having failed to undergo proper mitosis. Both wild-type
and p53 -/- cells were observed to contain micronuclei following nocodazole
FIG. 3.1
p53-dependent cell cycle arrest following nocodazole treatment.
(A) FACS profiles of wild-type and p53 -/- MEFs untreated or treated with
nocodazole for 24 h. X-axis is DNA content; y-axis is number of cells counted. Data
shown are representative of multiple experiments performed on 3 different wild-
type and p53 -/- clones.
(B) Immunofluorescent staining of wild-type and p53 -/- MEFs. MEFs were treated
with nocodazole for 24 h, pulsed with BrdU in the presence of nocodazole for an
additional 4 h, and fixed. Immunofluorescence was performed to detect BrdU
incorporation (a-BrdU; green staining) and nuclear staining (DAPI; blue staining).
Immunofluorescence was performed on 3 different wild-type and p53 -/- clones.
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treatment, resulting from chromosome decondensation and subsequent
reformation of the nuclear membrane (Kung et al., 1990). These results confirm
previous observations describing a p53-dependent arrest following destabilization of
the mitotic spindle (Cross et al., 1995; Minn et al., 1996; Di Leonardo et al., 1997).
Time-lapse videomicroscopy of mitotic arrest
One interpretation of the results described in Fig. 3.1 is that p53 functions in a
checkpoint at mitosis, based on the fact that p53 -/- MEFs behave abnormally when
the mitotic spindle is disrupted. To test this hypothesis directly, we used time-lapse
videomicroscopy to observe p53 +/+ and p53 -/- MEFs during mitosis. If p53 were
part of a mitotic checkpoint, then we would expect to see a difference in the
behavior of nocodazole-treated p53 +/+ and p53 -/- MEFs at mitosis. Figure 3.2A
shows a representative untreated p53 -/- fibroblast during normal cell division.
The cell rounded up from the coverslip (Fig. 3.2A, time 5:21 PM), underwent
cytokinesis (Fig. 3.2A, time 5:32 PM), and completed division into two daughter cells
(Fig. 3.2A, time 5:40 PM). Thus, the length of mitosis, as determined visually by
rounding of the parent cell and separation into two daughter cells, was
approximately 20 min. Normal mitosis lasted 26 ± 8 min (mean ± standard
deviation) in wild-type MEFs and 27 ± 7 min in p53 -/- MEFs, based on
observations made on at least 15 cells of each genotype (data not shown). For our
next experiments, we used time-lapse techniques to determine the fate of fibroblasts
that initiated mitosis while in the presence of the spindle inhibitor nocodazole.
Figure 3.2B shows two nocodazole-treated p53 +/+ fibroblasts that entered mitosis
within the same 30 min window. Each cell rounded up from the coverslip as was
observed for normal mitosis (Fig. 3.2B, time 1:14 PM and 1:43 PM). However, the
cells then changed shape rapidly in apparent attempts to complete cell division over
a period of approximately 4 h (Fig. 3.2B, time 3:33 PM and 4:31 PM). Strikingly, after
FIG. 3.2
Time-lapse videomicroscopy of wild-type and p53 -/- nocodazole-treated fibroblasts.
(A) Control p53 -/- MEF that underwent mitosis in normal media. Each
photograph lists the time during videorecording when the picture was taken. The
cell entered mitosis at 5:21 PM (arrowhead), cytokinesed at 5:32 PM (two
arrowheads), and completed division by 5:40 PM. The cell shown is representative
of over 30 cells (wild-type and p53 -/-) observed undergoing normal mitosis.
(B) Two wild-type MEFs that initiated mitosis in the presence of nocodazole. Each
cell entered mitosis (time 1:14 PM and time 1:43 PM), remained arrested at mitosis
for several hrs (time 3:33 PM and time 4:31 PM), then adapted (time 5:33 PM and
time 6:02 PM). Black and white arrowheads indicate the two different cells.
(C) p53 -/- MEF that entered mitosis in the presence of nocodazole (time 10:08 AM;
arrowhead). It arrested at mitosis for several hours (time 11:00 AM and time 12:17
PM) and eventually adapted (time 1:47 PM and time 2:13 PM).
(D) Quantitation of length of time that individual wild-type and p53 -/- MEFs
spent at mitotic arrest. Length of mitotic arrest was determined morphologically,
beginning when a cell first became rounded and refractile, and ending when it
flattened back onto the coverslip. Wild-type MEFs spent an average of 4.4 ± 2.4 hrs
at mitotic arrest, while p53 -/- MEFs spent an average of 4.6 ± 2.2 hrs at mitotic
arrest. At least 60 cells were observed for each genotype.
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this time, the cells returned to a flattened morphology without completing mitosis
(Fig. 3.2B, time 5:33 PM and 6:02 PM). This behavior of exiting from mitotic arrest
into an apparent interphase state without actually completing mitosis has been
previously described (Kung et al., 1990; Rieder and Palazzo 1992) ; we will refer to it
as "adaptation". We also examined the behavior of p53 -/- fibroblasts that entered
mitosis while in the presence of nocodazole. A representative p53 -/- fibroblast
that initiated mitosis while growing in nocodazole is shown in Figure 3.2C. Like
the p53 +/+ cells, the p53 -/- fibroblast rounded up (Fig. 3.2C, time 10:08 AM),
changed morphology over a 4 h period (Fig. 3.2C, time 11:00 AM and 12:17 PM), and
then flattened back out again onto the coverslip (Fig. 3.2C, time 1:47 PM and 2:13
PM).
Figure 3.2D shows quantitation of the time spent at mitotic arrest for individual p53
+/+ and p53 -/- MEFs that were followed by time-lapse videomicroscopy. The
length of arrest was determined for at least 60 cells of each genotype. Both p53 +/+
and p53 -/- MEFs spent a much longer period of time in a rounded mitotic state
when they were grown in nocodazole-containing medium than when they were
grown in normal medium. The average time spent arrested at mitosis under these
conditions was 4.4 hr for p53 +/+ MEFs and 4.6 hr for p53 -/- MEFs compared to 26-
27 min normally spent at mitosis in untreated cells. Cells of each genotype
subsequently exited from mitosis and flattened onto the coverslip without
completing cytokinesis. Interestingly, several cells of each genotype were observed
to undergo prolonged mitotic arrest of 8-14 h prior to adaptation (Fig. 3.2D). These
data demonstrate that p53 does not act as a mitotic checkpoint per se, because p53
+/+ and p53 -/- MEFs behave identically at mitosis in the presence of nocodazole.
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Requirement for p53 after adaptation
Given that p53 does not affect mitotic arrest kinetics, we wished to identify the stage
at which p53 is required for cell cycle arrest following nocodazole treatment. To
address this question, individual p53 -/- MEFs treated with nocodazole were
followed through mitotic entry and arrest, mitotic exit/adaptation, and S phase
entry. Cells were plated onto gridded cover slips and followed by time-lapse
videomicroscopy as above. After 18-22 h of treatment, cells were pulsed with BrdU
for an additional 4 h in the presence of nocodazole and then analyzed by
immunofluorescence. Figure 3.3A shows a representative p53 -/- MEF that
attempted mitosis, adapted, and then incorporated BrdU. The cell entered mitosis at
12 AM, remained in mitotic arrest for several hours, and then exited mitosis at 5:30
AM. BrdU label was added at 11 AM, and the cell was fixed 4 h later.
Immunofluorescent detection for BrdU uptake revealed that the cell had been in S
phase during the time the BrdU label was present, which was 5.5 to 9.5 hours after
adaptation had occurred. Ten individual p53 -/- fibroblasts were tracked with this
method to determine the number of hours which elapsed between morphological
adaptation and S phase entry (Fig. 3.3B). Importantly, cells did not enter S phase
immediately after exiting mitosis, as cells labelled with BrdU 0 to 3.5 h post-
adaptation failed to stain positively. The p53 -/- MEFs began to incorporate BrdU
in a time window approximately 4 to 6 h post-adaptation. One p53 -/- MEF
incubated with BrdU for 9 to 13 h after it had undergone adaptation failed to
incorporate label. The behavior of this fibroblast does not necessarily indicate the
time limit for when p53 -/- MEFs can reenter S phase, however, because the
fibroblast may either already have completed S phase at the time of the BrdU label
or may not yet have initiated it. These data show that p53 is required to prevent
entry into S phase beginning in a specific time interval after nocodazole-treated
MEFs have attempted mitosis and subsequently adapted into an interphase state.
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FIG. 3.3
Timing of S phase entry in p53 -/- MEFs treated with nocodazole.
(A) Time-lapse videomicroscopy and subsequent immunofluorescence of
representative p53 -/- MEF that arrested at mitosis in the presence of nocodazole.
The cell was at mitotic arrest starting shortly after 12 AM, then adapted at 5:30 AM
(top panels and lower left panel). At 11 AM, BrdU label was added to the media; the
cell was then recorded for an additional 4 h and fixed. Immunofluorescence was
performed to detect BrdU incorporation (lower right panel; green staining). As
indicated by arrowheads, the same cell was identified during videorecording and
immunofluorescence by its position on a gridded coverslip.
(B) Measurement of time of S phase entry relative to time of adaptation from
mitotic arrest. 10 p53 -/- MEFs on gridded cover slips were treated with nocodazole,
monitored by time-lapse videomicroscopy, and pulsed with BrdU for 4 h at various
times following adaptation. For each cell, the horizontal line indicates the period
during which BrdU was present, measured in hrs elapsed since the cell underwent
adaptation. The + or - indicates whether the cell stained positive for BrdU
incorporation by immunofluorescence.
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Cells lacking p21 fail to maintain postmitotic arrest
p53 has been shown to prevent cells in G1 from entering S phase following DNA
damage (Kastan et al., 1991; Kastan et al., 1992; Kuerbitz et al., 1992). This arrest is
mediated in large part by p21, a transcriptional target of the p53 protein which
inhibits CDKs and prevents phosphorylation of the Rb protein, a requirement for S
phase entry (Brugarolas et al., 1995; Deng et al., 1995). To test whether a similar
mechanism might be functioning to prevent S phase entry in nocodazole-treated
adapted cells, we performed immunoblot analysis for p21 protein on wild-type and
p53 -/- MEFs treated with nocodazole (Fig. 3.4A). In wild-type cells, levels of p21
protein increased after 16 h of nocodazole treatment and remained elevated over a
48 h period. No p21 protein was detectable in nocodazole-treated p53 -/- MEFs.
These observations suggested a possible role for p21 in maintaining arrest following
nocodazole treatment. To establish whether p21 was required for the arrest
following spindle disruption, wild-type, p53 -/-, and p21 -/- MEFs were treated
with nocodazole for 24 h and analyzed by flow cytometry (Fig. 3.4B). As was
observed in Figure 3.1, wild-type MEFs arrested with 4N DNA content, while p53
-/- MEFs continued to increase in ploidy. p21 -/- MEFs were observed to have a
phenotype similar to that of p53 -/- MEFs, with a significant fraction of cells
undergoing an additional round of S phase to become 8N in DNA content.
To demonstrate further that p21 -/- cells were capable of reentry into S-phase
following nocodazole treatment, p21 -/- MEFs were treated with nocodazole for 24
h, pulsed with BrdU while still in the presence of nocodazole for another 4 h, and
analyzed by immunofluorescence (Fig. 3.4C). A high percentage of nocodazole-
treated p21 -/- MEFs were found to incorporate BrdU under these conditions,
indicating inappropriate S-phase entry. Similar results were observed when wild-
type, p53 -/-, and p21 -/- MEFs were treated with the microtubule-destabilizing
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FIG. 3.4
Requirement for p21 in cell cycle arrest following nocodazole treatment.
(A) Immunoblot analysis for p21 protein on extracts from wild-type and p53 -/-
MEFs treated with nocodazole. Cells were treated with nocodazole for times
indicated.
(B) FACS profiles of p21 -/- MEFs untreated or treated with nocodazole for 24 h. X-
axis is DNA content; y-axis is number of cells counted. Data shown are
representative of 3 experiments performed on 2 different p21 -/-clones.
(C) Immunofluorescent staining of p21 -/- MEFs. Cells were treated with
nocodazole for 24 h, pulsed with BrdU in the presence of nocodazole for an
additional 4 h, and fixed. Immunofluorescence was performed to detect BrdU
incorporation (a-BrdU; green staining) and nuclear staining (DAPI; blue staining).
Immunofluorescence was performed on 2 different p21 -/-clones.
(D) Quantitation of number of cells in S phase in wild-type, p21 -/-, and p53 -/-
MEFs following nocodazole treatment. Cells were treated with nocodazole and
immunofluorescence was performed as described in Fig. 3.4C. Data shown are the
averages from 3 different experiments, with standard deviations as indicated. In
each experiment, 100 cells of each genotype were examined and the number of
BrdU-positive nuclei was counted to determine the percent of S phase cells. Two
different clones were tested for each genotype.
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drug colcemid, demonstrating the generality of this response (data not shown).
Quantitation of the percentage of wild-type, p53 -/-, and p21 -/- MEFs that stained
positively for BrdU incorporation after 28 h of nocodazole treatment is presented in
Figure 3.4D. Approximately 54% of p21 -/- MEFs incorporated BrdU during the
labelling period, as compared to 65% of p53 -/- MEFs and 14% of wild-type MEFs.
Untreated MEFs of all three genotypes had similar percentages of cells in S phase
(approximately 50-60%; data not shown). Thus, the p21 -/- MEFs had an abnormal
arrest phenotype which was similar to that of p53 -/- MEFs, although not as severe.
Given these results, we concluded that p21 is required to fully prevent cells treated
with spindle drugs from reentering S phase.
Mitotic arrest and adaptation in NIH 3T3 cells
Thus far, our data demonstrated that p53 functions to prevent S phase entry
following mitotic arrest and adaptation. However, while inappropriate S phase
entry had been observed to occur in thousands of cells using FACS analysis, mitotic
arrest and adaptation had only been observed in approximately 100 cells in these
experiments. To demonstrate that mitotic arrest and adaptation also occurred on
the level of entire populations of cells, we turned to methods other than time-lapse
videomicroscopy. NIH 3T3 cells were used in these experiments, for ease of
synchronization and to show that our previous observations did not reflect a
phenotype specific to our MEF clones. The NIH 3T3 cell line has been shown to
contain wild-type p53 (Rittling and Denhardt 1992; Tishler et al., 1993; Hermeking
and Eick 1994; Michieli et al., 1994; Lu et al., 1996). NIH 3T3 cells were synchronized
for 48 h in low serum medium, then released into high serum medium with or
without nocodazole. At 6 h time points, cells were photographed and then fixed for
flow cytometric analysis of DNA content (Fig. 3.5). At the time of release into high
serum, cells were synchronized with a 2N DNA content (Fig. 3.5A, untreated, and B,
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FIG. 3.5
Mitotic arrest and adaptation occur in synchronized, nocodazole-treated NIH 3T3
cells.
(A) Untreated NIH 3T3 cells. Cells were synchronized in low serum for 48 h, then
released into high serum and followed for 32 h. At each time point, cells were
photographed (left panels), then prepared for FACs analysis for DNA content (right
panels). Time points are measured in hrs post-release from serum starvation. Cells
were initially in GO (0 h), then entered S phase at 14 h, and completed cell division
by 26 h.
(B) Nocodazole-treated NIH 3T3 cells. Cells were synchronized in low serum for 48
h, then released into high serum + nocodazole and followed for 32 h. Progression of
cells through cell cycle was monitored as above. Cells exited GO and entered S phase
by 14 h, remained arrested at mitosis through 26 h, and adapted by 32 h.
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nocodazole-treated; 0 h). Cells entered S phase synchronously (Fig. 3.5A and B, 14 h)
and completed DNA synthesis by 20 h after release into high-serum containing
medium (Fig. 3.5A and B, 20 h). The presence of nocodazole did not noticeably delay
progression into or completion of S phase, as judged by DNA content. The first
mitoses were visible at the same time point in photographs of untreated and
nocodazole-treated cells as rounded refractile cells (Fig. 3.5A and B, 20 h). Within 6
h, all of the cells in the untreated population had completed mitosis, as the 4N
population had been replaced by cells with 2N and S phase DNA content (Fig. 3.5A,
26 h). In contrast, all the cells in the nocodazole-treated population had a 4N DNA
content at 26 h, and most appeared to be rounded up and arrested at mitosis (Fig.
3.5B, 26 h). By the next time point, however, these cells had flattened out again but
still had a 4N DNA content, indicating their failure to complete mitosis (Fig. 3.5B, 32
h). In the adapted cells, microtubules were depolymerized and chromatin was
decondensed, as determined by indirect immunofluorescence for tubulin and
nuclear staining with DAPI, respectively (data not shown). Thus, as observed with
wild-type MEFs, NIH 3T3 cells did not undergo an additional round of DNA
synthesis during nocodazole treatment. These results indicate that the great
majority of murine fibroblasts in a synchronized population undergo mitotic arrest
and adaptation when treated with nocodazole.
Expression of cyclins B and E following nocodazole treatment
We observed some similarities between the p53-dependent checkpoint following
nocodazole treatment and the p53-dependent G1 checkpoint following irradiation.
Our data showed that a primary effector of the G1 checkpoint response, p21, was also
required for arrest after spindle disruption. Also, adapted cells had the flattened
morphology and decondensed chromatin chararacteristic of cells in G1. To
determine whether adapted cells were similar to G1 cells at the molecular level, we
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FIG. 3.6
Expression of cyclin E protein is upregulated in nocodazole-treated, adapted cells.
Immunoblot analysis of cyclin B1 and cyclin E expression. NIH 3T3 cells were
synchronized in low serum for 48 h and released into high serum + nocodazole.
Extracts were collected at 8 h time points for the next 48 h and analyzed by
immunoblotting for cyclin B1 and cyclin E expression. Cyclin E expression was
highest in cells entering S phase (16 h) and in cells which had adapted (40 and 48 h),
while cyclin B1 expression was highest in mitotic cells (24 h). Asterisk (*) indicates
constant band detected by cyclin E antibody that serves as internal loading control.
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measured expression of cyclin B1, a mitotic cyclin, and cyclin E, a G1 cyclin, in
nocodazole-treated cells. Cyclin B1 is expressed at high levels in mitotic cells and
declines when cells enter G1, while cyclin E expression is highest in cells in the late
G1 phase of the cell cycle (Dunphy et al., 1988; Lew et al., 1991). NIH 3T3 cells were
synchronized in low serum, released into medium with high serum plus
nocodazole, and collected at time points for immunoblotting. The blot was probed
with antibodies to cyclin B1 and cyclin E (Fig. 3.6). Cyclin B1 levels peaked at 24 h
and decreased afterward. The appearance of this peak corresponded with the
presence of mitotic cells (data not shown). Cyclin E levels were elevated at 16 h as
cells progressed from G1 into S phase and then decreased with the onset of mitosis.
At 32 h, mitotic-arrested cells had just adapted into a flattened state (data not shown)
and cyclin E levels remained low (Fig. 3.6). Cyclin E levels then increased again in
the adapted cells at 40 h (Fig. 3.6). Thus, adapted cells express high levels of cyclin E,
a G1 marker, despite having a DNA content characteristic of cells in the G2 or M
phase of the cell cycle. The delayed expression of cyclin E relative to adaptation may
reflect the fact that cyclin E is normally expressed in late G1 and that adapted cells
take several hours to progress to this state.
Presence of hypophosphorylated pRB in adapted cells
To characterize further the nocodazole-induced adapted state, we examined adapted
cells for another marker of G1, hypophosphorylated Rb protein. In the G1 phase of
the cell cycle, the Rb protein (pRB) is in a hypophosphorylated state (Buchkovich et
al., 1989; Chen et al., 1989; DeCaprio et al., 1989; Mihara et al., 1989). As part of the
G1-S phase transition, pRB becomes hyperphosphorylated on multiple sites, and
remains so until anaphase of mitosis (Ludlow et al., 1993). We analyzed serum-
synchronized, nocodazole-treated NIH 3T3 cells at various time points for their pRB
phosphorylation status (Fig. 3.7A) and DNA content (Fig. 3.7B). At time 0, cells had
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FIG. 3.7
RB protein is hypophosphorylated in nocodazole-treated, adapted cells.
(A) Immunoblot analysis of pRB. NIH 3T3 cells were synchronized in low serum
for 48 h and released into high serum + nocodazole. Extracts were collected at time
points for the next 48 h and analyzed by immunoblotting for pRB.
Hypophosphorylated pRB (pRB) and hyperphosphorylated pRB (pRB*) are indicated
by arrows.
(B) DNA content of NIH 3T3 cells. Cells were treated as described in Fig. 3.7A. At
each time point, a duplicate plate was collected and prepared for FACS analysis of
DNA content. Cells were initially synchronized in GO (0 h), then progressed to S
phase (16 h), and arrested at mitosis (24 h and 40 h).
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been serum-starved for 48 h and were 2N in DNA content. All pRB was
hypophosphorylated, as would be expected for cells in GO. Sixteen hours after
release into medium containing high serum plus nocodazole, pRB had become
hyperphosphorylated, corresponding with the entry of cells into S phase. At 24 h
post-release, cells had completed DNA synthesis and were entering mitotic arrest,
from which they later adapted (Fig. 3.7B and data not shown). By 40 h of treatment,
cells had adapted and pRB was predominantly in the hypophosphorylated state.
Therefore, like cyclin E expression, pRB phosphorylation status in adapted cells
resembles the pattern seen in G1 cells. Because pRB is present in adapted cells in the
active, or hypophosphorylated, state, it is possible that like p53 and p21, pRB
functions to prevent S-phase reentry during nocodazole treatment. Such a
mechanism seems likely, given that p21 is required for arrest in nocodazole-treated
cells and that p21 induces cell cycle arrest in part by inhibiting pRB phosphorylation.
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Discussion
p53 is a postmitotic checkpoint
Many functions have been attributed to the p53 protein, which is clearly a critical
cell cycle regulator in mammalian cells (Levine 1997). In this study, we have
addressed the question of whether the ability of cells to initiate and maintain the
mitotic spindle checkpoint is affected by their p53 status. We have attempted to
clarify the role of p53 at mitosis by monitoring the response of individual p53 +/+
and p53 -/- cells to spindle inhibitors. In order for p53 to qualify as part of a true
mitotic checkpoint, p53 +/+ and p53 -/- MEFs would have to behave differently at
mitosis. However, we observed that both wild-type and p53-deficient MEFs arrested
at mitosis following disruption of the spindle and that cells of either genotype
arrested for the same length of time and behaved identically during the mitotic
arrest. This behavior is opposite to that of mammalian cells in which the MAD2 or
BUB1 mitotic checkpoint gene products, which monitor the integrity of the mitotic
spindle, have been inhibited. Recent studies have identified a human homolog for
the S. cerevisiae MAD2 checkpoint gene, hsMAD2, as well as a murine homolog of
the S. cerevisiae BUB1 checkpoint gene. As would be predicted from experiments
with S. cerevisiae mad strains, mammalian cells electroporated with an anti-
hsMAD2 antibody did not undergo arrest at mitosis when the cells were treated with
nocodazole (Li and Benezra 1996). Similarly, when treated with nocodazole,
mammalian cells which expressed a dominant negative version of the murine Bubi
gene arrested at mitosis much less frequently than their normal counterparts.
(Taylor and McKeon 1997). Thus, when contrasted with genes which are known to
act at mitotic checkpoints in mammalian cells, p53 acts in a different manner. We
can conclude that, unlike the hsMAD2 and murine Bubl genes, the presence or
absence of p53 has no impact on the ability of cells to detect microtubule disruption
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and initiate metaphase arrest. Thus, we have shown definitively that p53 does not
act to implement a checkpoint at mitosis in mouse embryonic fibroblasts.
p21 is required for postmitotic arrest
We observed that p53 does have a checkpoint function in MEFs following
nocodazole treatment, specifically, to prevent S phase reentry following adaptation
from mitotic arrest. Consistent with this finding is the observation that levels of
p53 protein and its downstream target gene product p21 both increase following
treatment with nocodazole or other microtubule drugs (Fig. 3.4A; Minn et al., 1996;
Tishler et al., 1995). Importantly, we have found that the downstream arrest
mechanism activated by p53 requires the CDK inhibitor p21, as p21 -/- MEFs fail to
arrest in response to nocodazole treatment and enter another round of S phase, in
contrast to the results of an earlier study (Deng et al., 1995). Although our data were
obtained with cells treated with nocodazole, we obtained similar results with the
spindle inhibitor colcemid (data not shown), which was the microtubule-
destabilizing drug used in the earlier study. We eliminated the possibility that the
p21 protein itself was acting at a mitotic checkpoint, because like wild-type and p53
-/- MEFs, p21 -/- MEFs treated with nocodazole arrested at mitosis for 4 to 5 h and
then adapted (data not shown). The simplest explanation for our observation is that
in adapted cells, activation of p53 leads to increases in p21 protein, which then
initiates cell cycle arrest by inhibiting cyclin-CDK activity. Interestingly, the
contribution of p21 to the arrest response following nocodazole treatment and
adaptation is proportionately similar to the contribution of p21 to the G1 arrest
response following DNA damage. In nocodazole-treated, adapted MEFs, p21 is
responsible for about 80% of the p53-mediated arrest response, while in irradiated
MEFs, p21 accounts for approximately 70-80% of the p53-dependent arrest in G1
(Brugarolas et al., 1995; Deng et al., 1995). These data demonstrate not only that p21
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is required for the arrest following nocodazole treatment but also that the
requirement for p21 is quantitatively similar to the requirement for p21 in the G1
arrest following DNA damage.
Postmitotic arrest resembles G1 arrest
Taken together, our results suggest that p53 could be acting as a component of a G1
checkpoint in nocodazole-treated cells. First, p53 function is required to prevent
reentry into S phase following checkpoint activation, as occurs in the G1 checkpoint
following DNA damage. Second, p21 is required to execute this arrest, and to an
extent similar to its role in the G1 arrest checkpoint. Finally, cells which have exited
mitotic arrest have the flattened appearance and decondensed chromatin of G1 cells
and express the Gi-specific markers cyclin E and hypophosphorylated pRB. Thus,
p53 could be implementing a Gl-like arrest in 4N, adapted cells.
Potential signalling pathways
An interesting and as-yet-unanswered question is the nature of the upstream signal
which triggers p53-dependent arrest following nocodazole treatment. One
possibility is that as during the normal G1 checkpoint, p53 detects DNA damage. It
is readily conceivable that a cell which attempted to undergo chromosome
separation at metaphase when its spindle was destabilized by nocodazole could
incur DNA damage, which would then be detected following exit from mitotic
arrest. In this case, both the upstream and downstream signals for arrest following
nocodazole treatment would be identical to those for G1 arrest following irradiation.
Alternatively, p53 could be activated by other types of signals, such as the presence of
two centrosomes in a Gl-like cell. Another possible signal could be the presence of
excess chromosomes in a Gl-like cell, which would trigger a p53-dependent
checkpoint to prevent endoreduplication. Our data do exclude one possibility,
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however, which is that p53 is activated in response to a loss of microtubule stability
induced by nocodazole treatment. Our data in NIH 3T3 cells, which contain
functional p53, show that like other cell types, they progress unhindered from G1 to
mitosis while in the constant presence of nocodazole (Fig. 3.5; Jordan et al., 1992).
Were p53 detecting a loss of microtubule stability in G1 or Gl-like cells, these cells
would never have progressed through S phase, but instead would have arrested
shortly after entry into G1.
While it has been speculated to act at multiple different cell cycle checkpoints, the
p53 protein appears to have overlapping checkpoint functions following irradiation
and spindle disruption. After irradiation, cells undergo p53-dependent arrest in G1
(Kastan et al., 1991; Kastan et al., 1992; Kuerbitz et al., 1992); after nocodazole-induced
disruption of the mitotic spindle, cells arrest transiently at mitosis, adapt into a G1-
like state, and then undergo p53-dependent arrest (Minn et al., 1996). In both
instances, the p53-mediated arrest requires the CDK inhibitor p21 (Brugarolas et al.,
1995; Deng et al., 1995). Thus, both the stage of the cell cycle at which p53 induces
arrest and the downstream mechanism by which it implements arrest are similar
after either irradiation or nocodazole treatment. In cells which lack functional p53
protein, failure to arrest following irradiation or nocodazole treatment would be
predicted to lead to two distinctly different outcomes of chromosomal damage and
polyploidy, respectively. Thus, the loss of p53 checkpoint function during
tumorigenesis could lead to decreased genomic stability by multiple mechanisms.
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Chapter 4
Discussion and Conclusions
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In this thesis, I have described research relating the effects of p53 status on the
response of cells to microtubule disruption. We have found that in our model
system, the p53 genotype of transformed cells determines their ability to undergo
apoptosis in response to treatment with the microtubule-stabilizing drug paclitaxel.
Additionally, we have identified a potential mechanism by which paclitaxel may
exert p53-independent effects, via induction of TNF-a secretion from macrophages.
In a separate project also described in this thesis, we examined whether p53 acts as
part of a mitotic checkpoint in response to the microtubule-destabilizing drug
nocodazole. We have found that p53 does help implement cell cycle arrest after
nocodazole treatment, but only after cells have adapted from mitotic arrest into a
G1-like state. The implications of these findings are discussed below, as well as
future experiments to address unanswered questions.
Paclitaxel and p53-dependent apoptosis
We found that p53 +/+ fibroblasts transformed with the oncogenes ElA and
activated-H-Ras underwent apoptosis when treated with paclitaxel. However,
similarly transformed p53 -/- fibroblasts were resistant to treatment. This finding
may be significant for several reasons. First, it suggests that paclitaxel could act in
vivo by inducing apoptosis in transformed cells. Such a mechanism has been
suggested for other anticancer agents, such as adriamycin and ionizing radiation,
which also induce apoptosis in ElA-Ras transformed cells in vitro. (Lowe et al.,
1993). Both adriamycin and ionizing radiation were subsequently shown to cause
massive apoptosis in vivo, by treating tumors grown in nude mice from the E1A-
Ras transformed cell lines (Lowe et al., 1994). Based on our observations, one logical
next step would be to determine whether paclitaxel inhibits tumor progression by
inducing apoptosis in tumors in vivo. We have attempted to do so using the same
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model system of ElA-Ras tumors in nude mice, but found that paclitaxel treatment
did not consistently inhibit tumor progression in either p53 +/+ or p53 -/- tumors in
this system. A possible explanation for this is that the ElA-Ras tumors are
fibrosarcomas, which are not a tumor type against which paclitaxel has been shown
to be effective (Rowinsky and Donehower 1995). It would be of interest to test
paclitaxel in a group of murine tumor models in which it has been proven to be
effective, and determine whether apoptosis was taking place. Paclitaxel has already
been shown to induce apoptosis in a murine tumor model in at least one instance,
in a mouse model of lung adenocarcinoma (Kalechman et al., 1996).
Another interesting feature of the ability of paclitaxel to induce apoptosis in E1A-
Ras transformed cells is that it was dependent on the presence of wild-type p53
protein. This observation was unexpected, as no functional connection has been
made between the microtubule cytoskeleton and p53. Interestingly, we also
observed that the chemotherapeutic drug vincristine, which destabilizes
microtubules, induced p53-dependent apoptosis in transformed cells (J.S. Lanni and
T. Jacks, unpublished data). These data suggest that any disruption of microtubule
stability can result in the activation of p53-dependent apoptosis in transformed cells.
It is possible that as has been proposed, p53 is a general detector of cellular stresses,
such as DNA damage, poor nutrient supply, or in this instance, changes in
microtubule stability (Levine 1997). Alternatively, cells which have been treated
with microtubule-acting drugs may incur DNA damage when they attempt to
undergo mitosis with a defective spindle, leading to activation of the p53-dependent
DNA damage response pathway. It would be valuable to determine whether
treatment with paclitaxel or vincristine did result in DNA damage, which would
lend support to the latter model.
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Tumor necrosis factor-a and p53-independent apoptosis
As part of investigating a possible secondary mechanism of paclitaxel, we tested the
response of transformed cells to treatment with tumor necrosis factor-a (TNF-a),
which is released from murine macrophages upon paclitaxel stimulation. We
found that TNF-a induced apoptosis equally effectively in p53 +/+ and p53 -/- E1A-
Ras transformed fibroblasts. This observation is significant in that it suggests a
mechanism by which paclitaxel could inhibit the growth of tumors with mutated
p53. Paclitaxel has been shown to be effective against tumors with documented p53
mutations in several xenograft models (National Cancer Institute 1983; Baker et al.,
1989; Reiss et al., 1992; Rose 1993; Joschko et al., 1994). These data are difficult to
explain given that in our system, paclitaxel was seen to induce apoptosis only in p53
-/- transformed cells. However, if paclitaxel were able to induce TNF-a secretion
from macrophages infiltrating the tumor stroma, it could act by an indirect
mechanism to inhibit growth of both p53 +/+ and p53 -/- tumors in vivo. It is
important to note that if TNF-a release is relevant to the activity of paclitaxel in the
whole organism, it may be affected by species-specific differences. Treatment with
paclitaxel alone has been found to stimulate secretion of TNF-a from murine
macrophages, but a second stimulus appears to be required to activate TNF-a release
from human macrophages (Ding et al., 1990; Allen et al., 1993).
Regardless of the underlying mechanism of paclitaxel activity, the observation that
TNF-a causes p53-independent apoptosis has potential clinical relevance. Many
anticancer treatments which induce apoptosis appear to do so via p53-dependent
pathways, rendering them of limited use against tumors containing p53 mutations
(Lowe et al., 1994; Lowe 1995). The identification of an agent capable of inducing
p53-independent apoptosis could be a valuable addition to the repertoire of
anticancer treatments, particularly considering the high frequency of tumors with
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p53 mutations and the strong correlation between p53 mutation and poor response
to therapy (Hollstein et al., 1994; Lowe 1995). It should be noted that treatment with
TNF-a is far from an established therapy; in point of fact, many of the early clinical
trials with TNF-a found it to be of limited efficacy against tumors and with toxic
side effects in patients (Spriggs and Yates 1992). Recent trials have yielded more
encouraging results, however, in which localized treatment with TNF-a in
combination with other drugs has effectively inhibited tumor progression in several
systems (Baisch et al., 1990; Asher et al., 1991; Lejeune et al., 1994; Lasek et al., 1995).
Our data would suggest that further development of TNF-a as an anticancer agent is
worthwhile, given its unique ability to activate the cell death program in p53-
deficient tumor cells.
Recent clinical data on paclitaxel and p53 status
The research presented in Chapter 2 implies that paclitaxel may act by both p53-
dependent and p53-independent mechanisms in mouse tumor models, and possibly
in cancer patients as well. In order to determine the mechanism underlying
paclitaxel activity in humans, it is important to establish whether paclitaxel is
effective against tumors with p53 mutations. Since the time our experiments were
performed, more data have accumulated on the efficacy of paclitaxel against tumors
with mutated p53. One study directly addressing this question was carried out on
patients with non-small cell lung carcinoma (NSCLC) who were treated with
paclitaxel and radiation. Safran et al. determined the p53 status of 30 NSCLC tumors
using a single-strand conformation polymorphism assay and then confirmed the
presence of p53 mutations by sequence analysis (Safran et al., 1996). Of the 12
patients who had p53 mutations, 75% responded to treatment, as compared to 83%
of the 18 patients without p53 mutations. Thus, combination therapy with both
paclitaxel and radiation was found to be equally effective against NSCLC tumors
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with wild-type and mutated p53. As p53-mutant tumors have been documented to
be resistant to radiation therapy (Lowe 1995), this finding suggests that the paclitaxel
component of the therapeutic regimen is acting independently of p53 status.
In another recent study, Dunphy et al. examined a panel of 36 head and neck
squamous cell carcinomas for p53 overexpression prior to treatment with paclitaxel
and carboplatin (Dunphy et al., 1997). High levels of p53 expression are often
correlated with the presence of p53 mutations, providing an approximate indicator
of the p53 status of the tumors (Donehower and Bradley 1993). Twenty-four patients
in the study had tumors with detectable p53 expression (as seen by
immunohistochemical staining); of these, 6 underwent complete remission
following chemotherapy. The remaining 12 patients had tumors which did not
express p53; two of them showed complete remission after treatment. Therefore,
the expression of high levels of p53 protein did not appear to predict the
responsiveness of head and neck carcinomas to chemotherapy with paclitaxel and
carboplatin. Finally, Sikov and Safran have investigated the efficacy of combination
therapy with paclitaxel and radiation against advanced gastric and pancreatic cancers
(Sikov and Safran 1997). These tumor types are often resistant to chemotherapy
with DNA-damaging agents and radiation, and have a high frequency of p53
mutations. The researchers found that the combination of paclitaxel and radiation
therapy had substantial activity in patients. Although the p53 status of individual
tumors was not determined in this study, this finding could be indicative of
paclitaxel activity against tumors with p53 mutations.
The reports summarized above all suggest that paclitaxel is equally effective against
tumors with wild-type and mutated p53. This finding is in agreement with earlier
studies on the efficacy of paclitaxel in vivo discussed in Chapter 1. The observation
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that paclitaxel may act independently of p53 status in humans is supportive of our
model in which paclitaxel may inhibit tumor growth by both direct and indirect
mechanisms. Our data predict that paclitaxel treatment could cause TNF-a secretion
leading to p53-independent apoptosis. If TNF-a release is a component of
paclitaxel's mode of action in humans, this could explain in part the similarity in
the drug's activity against tumors with wild-type and mutant p53 protein.
Alternatively, paclitaxel could be exerting p53-independent effects by another
unidentified mechanism.
Functional significance of TNF-a secretion
One question raised by our experiments is whether TNF-a secretion is relevant to
the effectiveness of paclitaxel in preclinical and clinical settings. The fact that
paclitaxel has been seen to be equally active against p53 +/+ and p53 -/- tumors in a
number of different clinical settings supports a role for induction of p53-
independent apoptosis caused by TNF-a release. Ideally, this hypothesis would be
tested directly in a mouse tumor model setting in which both p53 +/+ and p53 -/-
tumors are available. Our data would predict that if TNF-a release is occurring in
vivo, then paclitaxel would inhibit tumor growth in tumors with and without p53.
Furthermore, we would expect that histology on tumors following paclitaxel
treatment would reveal an increased number of apoptotic cells, as TNF-a can induce
apoptosis in transformed cells in vitro. As an important control, one could also test
the activity of cephalomannine, a paclitaxel-related compound, in the same model
system. This analog stabilizes microtubules but does not induce TNF-a release
(Burkhart et al., 1994). It would therefore be predicted to be effective only against
p53 +/+ tumors, a prediction which could be tested in the same tumor model
system.
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Other possible experiments to test the TNF-a secretion model would require
performing histology on paclitaxel-treated tumors and analyzing them for the
presence of infiltrating macrophages. If TNF-a secretion occurs in vivo, then
macrophages should be detectable near or in the tumor mass, as local release of
TNF-a is most effective at inhibiting tumor growth (Malik 1992). Furthermore,
these experiments would allow one to examine individual paclitaxel-treated tumors
to determine whether any correlation exists between therapeutic success and the
presence or absence of macrophages in the tumor. It would also be worthwhile to
try to establish a more general correlation between the tumor types against which
paclitaxel has been found to be effective and the degree of macrophage infiltration in
these tissues. Tumors of different tissue types and at different stages of progression
are known to exhibit varying degrees of macrophage infiltration (Mantovani et al.,
1992). If paclitaxel were found to be most effective against tumor types with a
significant macrophage presence, that would support a possible role for TNF-a
release from macrophages in vivo.
Another means of determining the relevance of TNF-a secretion is by comparing
the activity of paclitaxel analogs against tumors in cancer patients. Docetaxel (trade
name Taxotere) is a compound closely related to paclitaxel from a structural
standpoint but with significant functional differences (Burkhart et al., 1994).
Docetaxel binds and stabilizes microtubules more effectively than paclitaxel, and can
induce mitotic arrest in cells at one third the concentration of paclitaxel required to
do so. However, docetaxel does not induce any release of TNF-a from macrophages.
If TNF-a release is a component of the therapeutic activity of paclitaxel, then
docetaxel, which lacks the ability to induce TNF-a secretion, should be less effective
as a chemotherapeutic agent. Data obtained from cancer patients treated with
docetaxel would suggest that this is not the case. In fact, docetaxel has proven widely
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effective against a number of different tumor types, including advanced breast and
ovarian cancer, head and neck cancer, and non-small cell lung cancer (Goldspiel
1997; Rowinsky 1997). All of these tumors are types against which paclitaxel has also
demonstrated activity, suggesting that the mechanism of these drugs in human
patients may depend primarily on their ability to stabilize microtubules rather than
on their ability to induce TNF-o secretion. Of course, other characteristics of
docetaxel could affect its activity in vivo, such as its increased cellular uptake and
intracellular retention time relative to paclitaxel (Aapro 1996). These additional
features of docetaxel may explain in part why docetaxel and paclitaxel do not show
complete cross-resistance (Von Hoff 1997). However, the proven efficacy of
docetaxel in anticancer treatments would seem to indicate that induction of TNF-a
release is not essential to the therapeutic success of paclitaxel.
Possible model for paclitaxel activity
Given the data presented above, it is clear that no simple relationship exists between
paclitaxel efficacy and p53 status. Our experiments on the response of transformed
cells to paclitaxel treatment found that microtubule disruption resulted in p53-
dependent apoptosis. However, this observation does not explain why paclitaxel
has been found to be effective against p53 -/- tumors in the clinic. One possible way
to reconcile our data could be by considering the concentration of paclitaxel present
following a standard therapeutic dose. When present at high concentrations, many
chemotherapeutic agents, including paclitaxel, can induce death in some p53 -/-
tumor cells (J.S. Lanni and T. Jacks, unpublished data). These drugs can still be
considered to function by p53-dependent mechanisms, as they are cytotoxic against
p53 +/+ tumor cells at far lower concentrations. Thus, paclitaxel may be noticeably
more effective against p53 +/+ tumor cells at the concentrations tested in vitro, but
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may show activity against both p53 +/+ and p53 -/- tumor cells at the concentrations
present in vivo.
Another important consideration is the presence of tissue and cell-type specific
factors which may affect cellular responses to microtubule damage. In our model
system of oncogenically transformed fibroblasts, paclitaxel induced p53-dependent
cell death. However, in tumor cell lines derived from other tissue types, paclitaxel
has been found to be cytotoxic against cells regardless of their p53 status. Delia et al
examined a group of p53 +/+ and p53 +/- immortalized lymphoblastoid cell lines,
and found that while p53 genotype affected their response to radiation, it did not
determine the cytotoxicity of paclitaxel treatment (Delia et al., 1996). Similarly,
Debernardis et al. observed that in a panel of nine different ovarian carcinoma cell
lines with and without p53 mutations, paclitaxel demonstated cytotoxic effects
independently of p53 status (Debernardis et al., 1997). These data suggest that the
p53-dependence of paclitaxel may be affected by differences between tumors of
fibroblast origin and those from lymphoblastoid or ovarian tissues. Even within a
group of tumors derived from the same tissue type, there are likely to be additional
genetic and cellular characteristics that develop during tumor formation which
affect paclitaxel sensitivity. Gibb and colleagues observed that of four different
ovarian carcinoma cell lines, all containing p53 mutations, each underwent
apoptosis to a differing extent following treatment with paclitaxel (Gibb et al., 1997).
From these data, it seems probable that paclitaxel may have p53-dependent and p53-
independent effects depending on the particular tumor context.
Additional factors such as induction of TNF-a secretion may also contribute to the
activity of paclitaxel in vivo. We have proposed that one component of paclitaxel
activity may be induction of TNF-a release, but were unable to determine the
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clinical relevance of TNF-a secretion in the scope of this work. Although the data
from docetaxel treatment in cancer patients suggest that TNF-a release is not a
requirement for the antitumor activity of paclitaxel, it remains possible that TNF-a
release is still a factor in paclitaxel activity in some tumors. Depending on the
degree of macrophage infiltration in a particular tumor, release of TNF-a could
augment the cytotoxic effects mediated directly by paclitaxel.
p53 is a post-mitotic checkpoint
We examined the response of wild-type and p53 -/- fibroblasts to treatment with the
microtubule-depolymerizing agent nocodazole, and found that p53 functions as part
of a post-mitotic checkpoint following spindle disruption. Earlier studies had
proposed that p53 acted as a component of a cell cycle checkpoint at mitosis, because
p53 -/- cells failed to maintain cell cycle arrest after treatment with microtubule-
acting drugs (Cross et al., 1995). We characterized in detail the response of wild-type
and p53-deficient fibroblasts to nocodazole treatment, and found that in fact, p53
activity was required only after cells exited from a temporary, p53-independent
mitotic arrest. Using time-lapse videomicroscopy techniques, we were able to
observe nocodazole-treated wild-type and p53 -/- fibroblasts as they entered mitosis
and determined that they remained in mitotic arrest for several hours. Nocodazole-
treated cells of both genotypes then exited from mitotic arrest and assumed a
flattened morphology, in a process known as adaptation (Rudner and Murray 1996).
The duration of time spent at mitotic arrest in the presence of nocodazole (4.5
hours) was considerably longer than the time required for normal mitosis in this
cell type, which lasts approximately 25 minutes.
From our data, we concluded that p53 did not act as part of a mitotic checkpoint. If
p53 function were required at mitosis, then p53 -/- fibroblasts would not have been
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predicted to undergo mitotic arrest in the presence of nocodazole. However, both
wild-type and p53 -/- fibroblasts remained in mitotic arrest for several hours in the
presence of drug. This behavior is in contrast to that of mammalian cells in which
components of the mitotic checkpoint have been inhibited from carrying out their
normal functions. The MAD and BUB genes were found in S. cerevisiae screens
designed to isolate mitotic checkpoint mutants (Hoyt et al., 1991; Li and Murray
1991). The human homolog of the S. cerevisiae MAD2 checkpoint gene has been
identified, hsMAD2. When an anti-hsMAD2 antibody was electroporated into
human cells, they exhibited a decrease in the number of cells at mitotic arrest in the
presence of nocodazole (Li and Benezra 1996). A murine homolog of the yeast BUB1
gene has also been identified. Expression of dominant negative mouse Bubl in cells
was seen to inhibit the ability of cells to implement mitotic arrest following
nocodazole treatment (Taylor and McKeon 1997). Unlike the MAD2 and Bubl
proteins, the p53 gene product does not function at a mitotic checkpoint, because its
absence does not affect the ability of cells to arrest at mitosis in the presence of
spindle inhibitors. Our finding is agreement with an earlier study by Minn et al,
who found that in prolymphocytic cells treated with nocodazole, cells expressing a
dominant negative p53 gene still underwent mitotic arrest in the presence of the
drug (Minn et al., 1996).
We found that p53 did act as part of a checkpoint to prevent S phase reentry
following the sequence of spindle disruption, mitotic arrest, and adaptation
described above. Beginning 2 hours after adaptation, p53 -/- fibroblasts began to
initiate S phase, despite never having successfully completed mitosis. This
behavior resulted in the accumulation of p53 -/- cells with 8N DNA content, an
observation that has been reported by other groups (Cross et al., 1995; Minn et al.,
1996; Di Leonardo et al., 1997). Wild-type adapted fibroblasts did not initiate an
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additional round of DNA synthesis, but instead remained in a quiescent interphase
state. Therefore, after spindle disruption, p53 acts to prevent adapted cells from
progressing into S phase, in a checkpoint function analogous to its well-
characterized checkpoint role in G1 following DNA damage. Our result supports an
earlier conclusion by Minn and colleagues, who observed that expression of
increased levels of p53 protein did not occur until after cells exited from mitotic
arrest, indicating a post-mitotic checkpoint function for p53 (Minn et al., 1996).
Other genes implicated in the postmitotic checkpoint
In addition to the p53 gene product, a number of other proteins appear to function
as part of the postmitotic checkpoint. All of these proteins have previously been
identified as components of the G1 cell cycle checkpoint, indicating that there is a
large degree of functional overlap between these two checkpoints. The p53 target
gene p21 is a CDK inhibitor which acts as a primary downstream mediator of the
p53-dependent G1 cell cycle arrest following radiation (Brugarolas et al., 1995; Deng
et al., 1995). We found that induction of p21 was required to maintain the arrest
state in cells treated with the spindle inhibitors nocodazole and colcemid, in contrast
to previously published data (Deng et al., 1995). We observed that like p53 -/- cells,
p21 -/- cells demonstrated inappropriate DNA synthesis in the presence of
nocodazole, although to a lesser degree. Notably, the extent of the requirement for
p21 was similar in G1l-arrested cells and postmitotically-arrested cells, approximately
70-80% in each instance (Brugarolas et al., 1995; Deng et al., 1995). Thus, expression
of p21 protein is required to the same degree in both the p53-dependent arrest in G1
following DNA damage and the p53-dependent arrest in adapted cells following
spindle damage. Interestingly, the CDK inhibitor p16 also helps prevent cell cycle
reentry following microtubule disruption, as p16 -/- mouse fibroblasts also become
8N upon treatment with spindle inhibitors (Khan and Wahl 1998).
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The retinoblastoma protein (pRB) also appears to be required for maintaining
postmitotic arrest. pRB is a key component in G1 regulation whose activity is
regulated by cell-cycle specific phosphorylation. The hypophosphorylated, active
form of the protein is present in G1, and becomes phosphorylated upon entry into S
phase, coincident with a loss of activity (Buchkovich et al., 1989; Chen et al., 1989;
DeCaprio et al., 1989; Ludlow et al., 1993). We found that in adapted, nocodazole-
treated cells, the predominant form of pRB was hypophosphorylated, indicating a
potential role for the Rb protein as part of the postmitotic checkpoint. Experiments
using fibroblasts which lack functional pRB have also determined that the Rb
protein is necessary for maintaining cell cycle arrest following nocodazole
treatment. Di Leonardo et al. observed that human fibroblast cells expressing the
human papillomavirus type 16 E7 protein, which binds to pRB, exhibited a large
fraction of 8N cells after nocodazole treatment (Di Leonardo et al., 1997). Rb -/-
murine fibroblasts obtained from knockout mice also appear to initiate DNA
synthesis inappropriately in the presence of spindle inhibitors, although with a
phenotype less severe than HPV-E7 expressing cells (Di Leonardo et al., 1997; Khan
and Wahl 1998). Taken as a whole, these data indicate that the absence of functional
Rb protein in adapted cells appears to permit inappropriate entry into S phase.
Linking microtubule disruption to p53: possible upstream signals
Loss of microtubule stability
An interesting subject which was not in the scope of our experiments is the nature
of the signal leading to activation of p53 following microtubule damage. A number
of possibilities exist for how this signal may be transmitted. One reasonable model
is that changes in microtubule stability lead to p53 activation. If such a mechanism
existed, it would define a novel signalling pathway linking the p53 protein directly
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to the cytoskeleton. However, our data suggest that changes in microtubule stability
do not directly lead to activation of p53. In our experiments using synchronized
NIH 3T3 cells, we saw that cells progressed unhindered from GO through S phase
while grown in the constant presence of nocodazole. This result is similar to earlier
findings reported by Jordan et al. ,who observed that low concentrations of
microtubule-depolymerizing agents did not affect interphase microtubules or
inhibit cell-cycle progression at times other than mitosis (Jordan et al., 1992). In our
experiments, if the loss of microtubule stability induced by nocodazole treatment
were sufficient to cause activation of p53, we would have expected to see the NIH
3T3 cells arrest soon after their initial entry into G1, since they contain functional
p53 protein (Rittling and Denhardt 1992; Tishler et al., 1993; Hermeking and Eick
1994). However, since the cells did not arrest until much later in the cell cycle, we
concluded that microtubule destabilization alone was not a stimulus monitored by
p53 .
In contrast to our findings, other research suggests that loss of microtubule stability
may be able to activate p53, perhaps in a cell type- or species-specific manner. Khan
and Wahl performed experiments using serum-synchronized human fibroblasts
treated with nocodazole (Khan and Wahl 1998). They reported that when a
synchronized population of wild-type cells progressed from GO into G1 in
nocodazole-containing medium, the cells arrested in G1. However, cells expressing
the human papillomavirus type 16 E6 protein, which binds p53, did not arrest in G1
but instead went on to enter S phase. One possible explanation for these data is that
the destabilization of cellular microtubules caused by nocodazole treatment is
detected by p53 in G1, resulting in p53-dependent cell cycle arrest. This mechanism
could differ between human and murine cells, which could reconcile our apparently
disparate results. If microtubule destabilization can lead to p53 activation, then
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elucidation of the molecules in the signalling pathway will be an important next
step. Blagosklonny et al. have demonstrated that treatment of cells with
microtubule-acting drugs leads to activation of the kinase Raf-1 and
phosphorylation of the bcl-2 gene product (Blagosklonny et al., 1997). It would be
interesting to determine whether the p53 protein has any apparent functional
connection to the molecules present in this pathway in cells which have
experienced microtubule disruption.
Centrosomal number/ hyperploidy
Another model for p53 activation following microtubule disruption is based on the
premise that p53 could become activated by the presence of abnormal elements in a
G1-like cell. We and others have shown that cells treated for an extended interval
with microtubule inhibitors will adapt from mitotic arrest into a Gl-like interphase
state (Kung et al., 1990; Rieder and Palazzo 1992). These adapted cells have some
normal characteristics of G1 cells, in that they contain predominantly
hypophosphorylated pRB, express cyclin E, and have decondensed chromatin.
However, because these cells never successfully completed mitosis, they also have a
4N DNA content and two centrosomes, neither of which are typically present in a
G1 cell. It is possible that the presence of one or both of these characteristics triggers
a p53-dependent arrest in the adapted cell. In support of this model, p53 -/- cells
have been shown to contain abnormal numbers of centrosomes, suggesting a role
for p53 in regulating centrosome duplication (Fukasawa et al., 1996). Also, it has
been reported that the p53 protein can be localized to the centrosome using
immunodetection techniques, and that a subfraction of cellular p53 copurifies with
centrosomal proteins (Brown et al., 1994). While p53 has not been shown to detect
hyperploidy in cells, absence of p53 has been associated with amplification of the
number of copies of the genome. Over 50% of p53 -/- fibroblasts spontaneously
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became tetraploid after 7 passages in vitro (Cross et al., 1995). Additionally, cells
derived from the pancreas of mice expressing SV40-T-antigen, which inactivates the
p53 protein, also developed significant tetraploid populations in vivo (Cross et al.,
1995). These data may provide preliminary evidence for a role for p53 in detecting
hyperploidy or centrosomal number, both of which are eventually present in cells
following microtubule disruption, mitotic arrest, and subsequent adaptation.
DNA damage
A third possible model for how p53 becomes activated after spindle disruption is
that treatment with microtubule inhibitors results in DNA damage, which is then
detected by p53 upon progression of cells into the adapted state. In this model, p53
would carry out a function identical to its checkpoint role in G1 following other
kinds of DNA damage such as radiation. This model could be addressed in part by
determining whether the ATM gene product is necessary for the checkpoint in
adapted cells following spindle damage. The ATM protein is known to function
upstream of p53 in response to DNA damage, in a signalling pathway leading to G1
arrest (Kastan et al., 1992). If absence of this protein were found to reduce the ability
of cells to arrest after nocodazole treatment, it would indicate that detection of DNA
damage via the ATM signalling pathway was a necessary step in checkpoint
activation. Such an experiment would be readily performable using ATM-deficient
fibroblasts obtained from knockout mice. It would also be useful to test whether
DNA damage was physically detectable in cells following nocodazole treatment,
using assays designed to detect DNA strand breaks. Using a standard terminal-
deoxynucleotide transferase assay, we did not detect any broken ends of DNA in
nocodazole-treated fibroblasts (J.S. Lanni and T. Jacks, unpublished data); however, a
more sensitive assay might reveal the presence of damaged DNA. The presence of
DNA strand breaks would not prove conclusively that they constitute part of the
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upstream signalling pathway, but it would lend support to a mechanism whereby
p53 was activated following detection of DNA damage. In the future, it would be
valuable to address the mechanism of p53 activation following treatment with
spindle drugs via these and other experiments.
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